Patent Grant
7792562
This application is a continuation of application Ser. No. 09/447,227, filed Nov. 22, 1999 , which is a division of application Ser. No. 08/811,473, filed Mar. 4, 1997, now U.S. Pat. No. 6,001,067.
The present invention relates generally to devices and methods for determining analyte levels, and, more particularly, to implantable devices and methods for monitoring glucose levels in a biological fluid.
The continuous measurement of substances in biological fluids is of interest in the control and study of metabolic disorders. Electrode systems have been developed for this purpose whereby an enzyme-catalyzed reaction is monitored (e.g., by the changing concentrations of reactants or products) by an electrochemical sensor. In such electrode systems, the electrochemical sensor comprises an electrode with potentiometric or amperometric function in close contact with a thin layer containing an enzyme in dissolved or insoluble form. Generally, a semipermeable membrane separates the thin layer of the electrode containing the enzyme from the sample of biological fluid that includes the substance to be measured.
Electrode systems that include enzymes have been used to convert amperometrically inactive substances into reaction products which are amperometrically active. For example, in the analysis of blood for glucose content, glucose (which is relatively inactive amperometrically) may be catalytically converted by the enzyme glucose oxidase in the presence of oxygen and water to gluconic acid and hydrogen peroxide. Tracking the concentration of glucose is possible since for every glucose molecule converted a proportional change in either oxygen or hydrogen peroxide sensor current will occur [U.S. Pat. Nos. 4,757,022 and 4,994,167 to Shults et al., both of which are hereby incorporated by reference]. Hydrogen peroxide is anodically active and produces a current which is proportional to the concentration of hydrogen peroxide, which is directly related to the concentration of glucose in the sample. [Updike et al., Diabetes Care, 11:801-807 (1988)].
Despite recent advances in the field of implantable glucose monitoring devices, presently used devices are unable to provide data safely and reliably for long periods of time (e.g., months or years) [See, e.g., Moatti-Sirat et al., Diabetologia 35:224-30 (1992)]. For example, Armour et al., Diabetes 39:1519-26 (1990), describes a miniaturized sensor that is placed intravascularly, thereby allowing the tip of the sensor to be in continuous contact with the blood. Unfortunately, probes that are placed directly into the vasculature put the recipient at risk for thrombophlebosis, thromboembolism, and thrombophlebitis.
Currently available glucose monitoring devices that may be implanted in tissue (e.g., subcutaneously) are also associated with several shortcomings. For example, there is no dependable flow of blood to deliver sample to the tip of the probe of the implanted device. Similarly, in order to be effective, the probe must consume some oxygen and glucose, but not enough to perturb the available glucose which it is intended to measure; subcutaneously implanted probes often reside in a relatively stagnant environment in which oxygen or glucose depletion zones around the probe tip may result in erroneously low measured glucose levels. Finally, the probe may be subject to “motion artifact” because the device is not adequately secured to the tissue, thus contributing to unreliable results. Partly because of these limitations, it has previously been difficult to obtain accurate information regarding the changes in the amounts of analytes (e.g., whether blood glucose levels are increasing or decreasing); this information is often extremely important, for example, in ascertaining whether immediate corrective action is needed in the treatment of diabetic patients.
There is a need for a device that accurately and continuously determines the presence and the amounts of a particular analyte, such as glucose, in biological fluids. The device should be easy to use, be capable of accurate measurement of the analyte over long periods of time, and should not readily be susceptible to motion artifact.
The present invention relates generally to devices and methods for determining analyte levels, and, more particularly, to implantable devices and methods for monitoring glucose levels in a biological fluid.
The devices and methods of the present invention allow for the implantation of analyte-monitoring devices such as glucose monitoring devices that result in a dependable flow of blood to deliver sample to the implanted device at a concentration representative of that in the vasculature. Moreover, the devices of the present invention become secured within the tissue of the subject, thereby greatly reducing or eliminating the phenomenon of “motion artifact”. In addition, the devices of the present invention utilize materials that eliminate or significantly delay environmental stress cracking at the sensor interface, resulting in the ability to obtain accurate, long-term data.
These effects result, in part, from the use of materials that enhance the formation of a foreign body capsule (FBC). Previously, FBC formation has been viewed as being adverse to sensor function, and researchers have attempted to minimize FBC formation (see, e.g., U.S. Pat. No. 5,380,536 to Hubbell et al.). However, the methods and devices of the present invention utilize specific materials and microarchitecture that elicit a type of FBC that does not hamper the generation of reliable data for long periods. The devices of the present invention are capable of accurate operation in the approximately 37° C., low pO2, environment characteristic of living tissue for extended lengths of time (e.g., months to years).
The electrode-membrane region of the devices of the present invention comprises a unique microarchitectural arrangement. In preferred embodiments, the electrode surfaces are in contact with (or operably connected with) a thin electrolyte phase, which in turn is covered by an enzyme membrane that contains an enzyme, e.g., glucose oxidase, and a polymer system. A bioprotective membrane covers this enzyme membrane system and serves, in part, to protect the sensor from external forces and factors that may result in environmental stress cracking. Finally, an angiogenic layer is placed over the bioprotective membrane and serves to promote vascularization in the sensor interface region. It is to be understood that other configurations (e.g., variations of that described above) are contemplated by the present invention and are within the scope thereof.
The present invention contemplates a biological fluid measuring device, comprising a) a housing comprising electronic circuit means and at least two electrodes operably connected to the electronic circuit means; and b) a sensor means operably connected to the electrodes of the housing, the sensor means comprising i) a bioprotective membrane, and ii) an angiogenic layer, the angiogenic layer positioned more distal to the housing than the bioprotective membrane. In particular embodiments, the bioprotective membrane is substantially impermeable to macrophages. In some embodiments, the bioprotective membrane comprises pores having diameters ranging from about 0.1 micron to about 1.0 micron. In certain embodiments, the bioprotective membrane comprises polytetrafluoroethylene, and in particular embodiments, the angiogenic layer also comprises polytetrafluoroethylene.
Particular embodiments of the biological fluid measuring device further comprise c) means for securing the device to biological tissue, the securing means associated with the housing. In some embodiments, the securing means comprises a polyester velour jacket. In preferred embodiments, the securing means covers the top surface (e.g., the top member or the top member sheath, as described further below) and a portion of the sensor interface; it should be noted that the securing means generally should not cover the entire sensor interface, as this would interfere with the ability of blood vessels to deliver sample to the biological fluid measuring device. In preferred embodiments, the securing means comprises poly(ethylene terephthalate).
In further embodiments, the sensor means of the biological fluid measuring device further comprises means for determining the amount of glucose in a biological sample. In some embodiments, the glucose determining means comprises a membrane containing glucose oxidase, the glucose oxidase-containing membrane positioned more proximal to the housing than the bioprotective membrane. In additional embodiments, the housing further comprises means for transmitting data to a location external to the device (e.g., a radiotelemetry device).
The present invention also contemplates a device for measuring glucose in a biological fluid, comprising a) a housing comprising electronic circuit means and at least one electrode operably connected to the electronic circuit means; and b) a sensor means operably connected to the electrode of the housing, the sensor means comprising i) means for determining the amount of glucose in a biological sample, the glucose determining means operably associated with the electrode, ii) a bioprotective membrane, the bioprotective membrane positioned more distal to the housing than the glucose determining means and substantially impermeable to macrophages, and iii) an angiogenic layer, the angiogenic layer positioned more distal to the housing than the bioprotective membrane.
In particular embodiments, the glucose determining means comprises a membrane containing glucose oxidase. In some embodiments, the angiogenic layer comprises polytetrafluoroethylene.
In some embodiments, the pores of the bioprotective membrane have diameters ranging from about 0.1 micron to about 1.0 micron, while in other embodiments the pores have diameters ranging from about 0.2 micron to about 0.5 micron. In certain embodiments, the bioprotective membrane comprises polytetrafluoroethylene.
Still other embodiments further comprise c) means for securing the device to biological tissue, the securing means associated with the housing. In particular embodiments, the securing means comprises poly(ethylene terephthalate). Additional embodiments comprise means for transmitting data to a location external to the device; in some embodiments, the data transmitting means comprises a radiotelemetric device.
The present invention also contemplates a method for monitoring glucose levels, comprising a) providing i) a host, and ii) a device comprising a housing and means for determining the amount of glucose in a biological fluid; and b) implanting the device in the host under conditions such that the device measures the glucose accurately for a period exceeding 90 days. In some embodiments, the device measures glucose accurately for a period exceeding 150 days, while in other embodiments, the device measures glucose accurately for a period exceeding 360 days.
The present invention also contemplates a method of measuring glucose in a biological fluid, comprising a) providing i) a host, and ii) a device comprising a housing and means for determining the amount of glucose in a biological fluid, the glucose determining means capable of accurate continuous glucose sensing; and b) implanting the device in the host under conditions such that the continuous glucose sensing begins between approximately day 2 and approximately day 25. In some embodiments, the continuous glucose sensing begins between approximately day 3 and approximately day 21. In particular embodiments, the implanting is subcutaneous.
The devices of the present invention allow continuous information regarding, for example, glucose levels. Such continuous information enables the determination of trends in glucose levels, which can be extremely important in the management of diabetic patients.
In order to facilitate an understanding of the present invention, a number of terms are defined below.
The term “accurately” means, for example, 95% of measured values within 25% of the actual value as determined by analysis of blood plasma, preferably within 15% of the actual value, and most preferably within 5% of the actual value. It is understood that like any analytical device, calibration, calibration check and recalibration are required for the most accurate operation of the device.
The term “analyte” refers to a substance or chemical constituent in a biological fluid (e.g., blood or urine) that can be analyzed. A preferred analyte for measurement by the devices and methods of the present invention is glucose.
The terms “sensor interface,” “sensor means,” and the like refer to the region of a monitoring device responsible for the detection of a particular analyte. For example, in some embodiments of a glucose monitoring device, the sensor interface refers that region wherein a biological sample (e.g., blood or interstitial fluid) or a portion thereof contacts (directly or after passage through one or more membranes or layers) an enzyme (e.g., glucose oxidase); the reaction of the biological sample (or portion thereof) results in the formation of reaction products that allow a determination of the glucose level in the biological sample. In preferred embodiments of the present invention, the sensor means comprises an angiogenic layer, a bioprotective layer, an enzyme layer, and an electrolyte phase (i.e., a free-flowing liquid phase comprising an electrolyte-containing fluid [described further below]). In some preferred embodiments, the sensor interface protrudes beyond the plane of the housing.
The terms “operably connected,” “operably linked,” and the like refer to one or more components being linked to another component(s) in a manner that allows transmission of, e.g., signals between the components. For example, one or more electrodes may be used to detect the amount of analyte in a sample and convert that information into a signal; the signal may then be transmitted to electronic circuit means (i.e., the electrode is “operably linked” to the electronic circuit means), which may convert the signal into a numerical value in the form of known standard values.
The term “electronic circuit means” refers to the electronic circuitry components of a biological fluid measuring device required to process information obtained by a sensor means regarding a particular analyte in a biological fluid, thereby providing data regarding the amount of that analyte in the fluid. U.S. Pat. No. 4,757,022 to Shults et al., previously incorporated by reference, describes suitable electronic circuit means (see, e.g.,
The terms “angiogenic layer,” “angiogenic membrane,” and the like refer to a region, membrane, etc. of a biological fluid measuring device that promotes and maintains the development of blood vessels microcirculation around the sensor region of the device. As described in detail below, the angiogenic layer of the devices of the present invention may be constructed of membrane materials alone or in combination such as polytetrafluoroethylene, hydrophilic polyvinylidene fluoride, mixed cellulose esters, polyvinyl chloride, and other polymers including, but not limited to, polypropylene, polysulphone, and polymethacrylate.
The phrase “positioned more distal” refers to the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a biological fluid measuring device comprise both a bioprotective membrane and an angiogenic layer/membrane. If the housing of the biological fluid measuring device is deemed to be the point of reference and the angiogenic layer is positioned more distal to the housing than the bioprotective layer, then the bioprotective layer is closer to the housing than the angiogenic layer.
The terms “bioprotective membrane,” “bioprotective layer,” and the like refer to a semipermeable membrane comprised of protective biomaterials of a few microns thickness or more which are permeable to oxygen and glucose and are placed over the tip of the sensor to keep the white blood cells (e.g., tissue macrophages) from gaining proximity to and then damaging the enzyme membrane. In some embodiments, the bioprotective membrane has pores (typically from approximately 0.1 to approximately 1.0 micron). In preferred embodiments, a bioprotective membrane comprises polytetrafluoroethylene and contains pores of approximately 0.4 microns in diameter. Pore size is defined as the pore size provided by the manufacturer or supplier.
The phrase “substantially impermeable to macrophages” means that few, if any, macrophages are able to cross a barrier (e.g., the bioprotective membrane). In preferred embodiments, fewer than 1% of the macrophages that come in contact with the bioprotective membrane are able to cross.
The phrase “means for securing said device to biological tissue” refers to materials suitable for attaching the devices of the present invention to, e.g., the fibrous tissue of a foreign body capsule. Suitable materials include, but are not limited to, poly(ethylene terephthalate). In preferred embodiments, the top of the housing is covered with the materials in the form of surgical grade fabrics; more preferred embodiments also contain material in the sensor interface region (see
The phrase “means for determining the amount of glucose in a biological sample” refers broadly to any mechanism (e.g., enzymatic or non-enzymatic) by which glucose can be quantitated. For example, some embodiments of the present invention utilize a membrane that contains glucose oxidase that catalyzes the conversion of glucose to gluconate: Glucose+O2→Gluconate+H2O2. Because for each glucose molecule converted to gluconate, there is a proportional change in the co-reactant O2 and the product H2O2, one can monitor the current change in either the co-reactant or the product to determine glucose concentration.
The phrase “means for transmitting data to a location external to said device” refers broadly to any mechanism by which data collected by a biological fluid measuring device implanted within a subject may be transferred to a location external to the subject. In preferred embodiments of the present invention, radiotelemetry is used to provide data regarding blood glucose levels, trends, and the like. The terms “radiotelemetry,” “radiotelemetric device,” and the like refer to the transmission by radio waves of the data recorded by the implanted device to an ex vivo recording station (e.g., a computer), where the data is recorded and, if desired, further processed (see, e.g., U.S. Pat. Nos. 5,321,414 and 4,823,808, hereby incorporated by reference; PCT Patent Publication WO 9422367).
The term “host” refers to both humans and animals.
The phrase “continuous glucose sensing” refers to the period in which monitoring of plasma glucose concentration is continuously carried out. More specifically, at the beginning of the period in which continuous glucose sensing is effected, the background sensor output noise disappears, and the sensor output stabilizes (e.g., over several days) to a long-term level reflecting adequate microcirculatory delivery of glucose and oxygen to the tip of the sensor (see
The present invention relates generally to devices and methods for determining analyte levels, and, more particularly, to implantable devices and methods for monitoring glucose levels in a biological fluid. In a preferred embodiment, the device and methods of the present invention are used to determine the level of glucose in a subject, a particularly important measurement for individuals having diabetes.
Although the description that follows is primarily directed at glucose monitoring devices and methods for their use, the devices and methods of the present invention are not limited to glucose measurement. Rather, the devices and methods may be applied to detect and quantitate other analytes present in biological fluids (including, but not limited to, amino acids and lactate), especially those analytes that are substrates for oxidase enzymes [see, e.g., U.S. Pat. No. 4,703,756 to Gough et al., hereby incorporated by reference]. Moreover, the devices and methods of the present invention may be utilized to present components of biological fluids to measurement methods which are not enzyme-based, including, but not limited to, those based on surface plasmon resonance, surface acoustic waves, optical absorbance in the long wave infrared region, and optical rotation of polarized light.
I. Nature of the Foreign Body Capsule
Probes that are implanted (e.g., subcutaneously) into tissue will almost always elicit a foreign body capsule (FBC) as part of the body's response to the introduction of a foreign material. Though a precise understanding of the nature of a FBC is not required in order to practice the present invention, generally speaking, upon implantation of a glucose sensor, there is initially an acute inflammatory reaction (which includes invasion of tissue macrophages), followed by building of fibrotic tissue. A mature capsule (i.e., the FBC) comprising primarily avascular fibrous tissue forms around the device [Woodward, Diabetes Care, 5:278-281 (1982)]. Although fluid is frequently found within the capsular space between the sensor and the capsule, levels of analytes (e.g., glucose and oxygen) within the fluid often do not mimic levels in the body's vasculature, making accurate measurement difficult. Example 4 below describes typically identifiable phases in FBC formation as reflected by response of an implanted glucose sensor.
In general, the formation of FBCs has precluded the collection of reliable, continuous information because they isolate the sensor of the implanted device from biological fluids, fully equilibrated with at least the low molecular weight components found in the circulation. Similarly, the composition of FBCs has prevented stabilization of the implanted device, contributing to motion artifact that renders unreliable results. Thus, conventionally, it has been the practice of those skilled in the art to attempt to minimize FBC formation by, for example, using a short lived needle geometry or sensor coatings to minimize the foreign body reaction.
In contrast to the prior art, the teachings of the present invention recognize that FBC formation is the dominant event surrounding long term implantation of any sensor and must be orchestrated to support rather than hinder or block sensor performance. For example, sensors often do not perform well until the FBC has matured sufficiently to provide ingrowth of well attached tissue bearing a rich supply of capillaries directly to the surface of the sensor. This maturation process takes at least several days and, when initiated according to the present invention, is a function of biomaterial and host factors which initiate and modulate angiogenesis, and promote and control fibrocyte ingrowth. The present invention contemplates the use of particular materials to promote angiogenesis adjacent to the sensor interface (also referred to as the electrode-membrane region, described below) and to anchor the device within the FBC.
II. The Implantable Glucose Monitoring Devices of the Present Invention
The present invention contemplates the use of a unique microarchitectural organization around the sensor interface of an implantable device. Moreover, the present invention contemplates the use of materials covering all or a portion of the device to assist in the stabilization of the device following implantation. However, it should be pointed out that the present invention does not require a device comprising particular electronic components (e.g., electrodes, circuitry, etc). Indeed, the teachings of the present invention can be used with virtually any monitoring device suitable for implantation (or subject to modification allowing implantation); suitable devices include, but are not limited, to those described in U.S. Pat. Nos. 4,703,756 and 4,994,167 to Shults et al.; U.S. Pat. No. 4,703,756 to Gough et al., and U.S. Pat. No. 4,431,004 to Bessman et al.; the contents of each being hereby incorporated by reference, and Bindra et al., Anal. Chem. 63:1692-96 (1991).
In the discussion that follows, an example of an implantable device that includes the features of the present invention is first described. Thereafter, the specific characteristics of, for example, the sensor interface contemplated by the present invention will be described in detail.
Generally speaking, the implantable devices contemplated for use with the present invention are oval shaped; of course, devices with other shapes may also be used with the present invention. The sample device includes a housing having an upper portion and a lower portion which together define a cavity.
In certain embodiments, a top member sheath 4 covers the top member 2; like the top member 2, the top member sheath 4 has an aperture which allows the sensor interface dome 30 to protrude therethrough. As indicated in detail in
Maintaining the blood supply near an implanted foreign body like an implanted analyte-monitoring sensor requires stable fixation of FBC tissue on the surface of the foreign body. This can be achieved, for example, by using capsular attachment membrane materials (e.g., those materials that comprise the sensor interface and top member capsular attachment layers) developed to repair or reinforce tissues, including, but not limited to, polyester (DACRON®; DuPont; poly(ethylene terephthalate)) velour, expanded polytetrafluoroethylene (TEFLON®; Gore), polytetrafluoroethylene felts, polypropylene cloth, and related porous implant materials. The preferred material for FBC attachment is surgical-grade polyester velour. FBC tissue tends to aggressively grow into the materials disclosed above and form a strong mechanical bond (i.e., capsular attachment); this fixation of the implant in its capsule is essential to prevent motion artifact or disturbance of the newly-developed capillary blood supply. In preferred embodiments, capsular attachment materials are not used in the region of the sensor interface so as not to interfere with the vasculature development in that region.
Side braces 3 secure the top member sheath 4 to the bottom member 1 (see
The interior (i.e., the cavity) of the housing comprises one or more batteries 9 operably connected to an electronic circuit means (e.g., a circuit board 8), which, in turn, is operably connected to at least one electrode (described below); in preferred embodiments, at least two electrodes are carried by the housing. Any electronic circuitry and batteries that renders reliable, continuous, long-term (e.g., months to years) results may be used in conjunction with the devices of the present invention.
The housing of the devices of the present invention preferably utilize a simple, low-cost packaging technique which protects the components of the device for at least one year in aqueous media. In preferred embodiments, the components of the housing (e.g., the top and bottom members) comprise thermoformed high-density polyethylene. The area in the cavity of the housing that surrounds the batteries, electronic circuitry, etc., may be filled with an encapsulant 40 (see
The preferred encapsulant compositions of the present invention comprise approximately 54% PW 130/35H wax (Astor Wax), approximately 40% MVO 2528 resin (Exxon Chemical), and approximately 6% XS 93.04 resin (Exxon Chemical, Houston, Tex.). These pelletized compounds render a well-mixed solution after heating and mixing at about 120° C. for approximately one hour. This solution is then poured into the polyethylene housing containing the implant electronics, taking caution to not to exceed the burst temperature of, e.g., approximately 160° C. when lithium batteries are used.
A retaining gasket 18 composed of, for example, silicone rubber, is used to retain the sensor interface capsular attachment layer 15 (
The present invention contemplates the construction of the membrane layers of the sensor interface region using standard film coating techniques. This type of membrane fabrication facilitates control of membrane properties and membrane testing.
III. Sensor Interface
As alluded to above and disclosed in
The membranes used in the sensor interface region are semipermeable membranes. Generally speaking, the two fundamental diffusion processes by which a semipermeable membrane can limit the amount of a substance that passes therethrough are i) diffusion through the semipermeable membrane as a porous structure and ii) diffusion through the semipermeable membrane as a monolithic, homogeneous structure. The present invention is not limited by the nature of the semipermeable membranes used in the sensor interface region.
A semipermeable membrane that comprises a porous structure consists of a relatively impermeable matrix that includes a plurality of “microholes” or pores of molecular dimensions. Transfer through these membranes is primarily due to passage of substances through the pores (i.e., the membrane acts as a microporous barrier or sieve). Examples of materials that may be used to form porous, semipermeable membranes include, but are not limited to, polyethylene, polyvinylchloride, polytetrafluoroethylene, polypropylene, polyacrylamide, cellulose acetate, polymethyl methacrylate, silicone polymers, polycarbonate, and cellulosic polymers.
Because diffusion is primarily due to passage of the substance through pores, the permeability is related to the effective size of the pores, the membrane thickness, and to the molecular size of the diffusing substance. As a result, there is little selectivity in the separation of two chemically or structurally related molecules, except when their molecular size is approximately the same as the size of the pore; when this occurs, forces acting between the substance and the surface of the pore channel may influence the rate of transfer. In addition, the upper size limit to diffusion is determined by the largest pore diameter, and the overall diffusion rate depends on the total number of pores.
In contrast, passage of a substance through a monolithic, homogeneous membrane depends upon selective dissolution and diffusion of the substance as a solute through a solid, non-porous film. As used herein, the term “monolithic” means substantially non-porous and having a generally unbroken surface. The term “homogeneous”, with reference to a membrane, means having substantially uniform characteristics from one side of the membrane to the other. However, a membrane may have heterogeneous structural domains, for example, created by using block copolymers (i.e., polymers in which different blocks of identical monomer units alternate with each other), and still be characterized functionally as homogeneous with respect to its dependence upon dissolution rather than sieving to effect separation of substances. A monolithic membrane can thus be used to selectively separate components of a solution on the basis of properties other than the size, shape and density of the diffusing substances. Monolithic, homogeneous membranes act as a barrier because of the preferential diffusion therethrough of some substance. They may be formed from materials such as those previously listed for porous membranes, including, but not limited to, polyethylene, polyvinylchloride, tetrafluorethylene, polypropylene, polyacrylamide, polymethyl methacrylate, silicone polymers, polycarbonate, collagen, polyurethanes and block copolymers thereof (block copolymers are discussed in U.S. Pat. Nos. 4,803,243 and 4,686,044, hereby incorporated by reference).
A. Angiogenic Layer
For implantable glucose monitoring devices, a sensor/tissue interface must be created which provides the sensor with oxygen and glucose concentrations comparable to that normally available to tissue comprised of living cells. Absent such an interface, the sensor is associated with unstable and chaotic performance indicating that inadequate oxygen and/or glucose are reaching the sensor. The development of suitable interfaces in other contexts has been reported. For example, investigators have developed techniques which stimulate and maintain blood vessels inside a FBC to provide for the demanding oxygen needs of pancreatic islets within an implanted membrane. [See, e.g., Brauker et al., Abstract from 4th World Biomaterials Congress, Berlin (1992)]. These techniques depend, in part, on the use of a vascularizing layer on the exterior of the implanted membrane. However, previously-described implantable analyte-monitoring devices have not been able to successfully maintain sufficient blood flow to the sensor interface.
As described above, the outermost layer of the electrode-membrane region comprises an angiogenic material. The angiogenic layer of the devices of the present invention may be constructed of membrane materials such as hydrophilic polyvinylidene fluoride (e.g., Durapore®; Millipore), mixed cellulose esters (e.g., MF; Millipore), polyvinyl chloride (e.g., PVC; Millipore), and other polymers including, but not limited to, polypropylene, polysulphone, and polymethacrylate. Preferably, the thickness of the angiogenic layer is about 10 μm to about 20 μm. The angiogenic layer comprises pores sizes of about 0.5 to about 20 μm, and more preferably about 1.0 μm to about 10 μm, sizes that allow most substances to pass through, including, e.g., macrophages. The preferred material is expanded PTFE of a thickness of about 15 μm and pore sizes of about 5 μm to about 10 μm.
To further promote stable foreign body capsule structure without interfering with angiogenesis, an additional outermost layer of material comprised of a thin low-density non-woven polyester (e.g., manufactured by Gore) can be laminated over the preferred PTFE described above. In preferred embodiments, the thickness of this layer is about 120 μm. This additional thin layer of material does not interfere with angiogenesis and enhances the manufacturability of the angiogenic layer. [See U.S. Pat. No. 5,453,278 to Brauker et al., hereby incorporated by reference; PCT Patent Publication Nos. 96/32076, 96/01611, and 92/07525 assigned to Baxter].
B. Bioprotective Membrane
The inflammatory response that initiates and sustains a FBC is associated with both advantages and disadvantages. Some inflammatory response is needed to create a new capillary bed in close proximity to the surface of the sensor in order to i) continuously deliver adequate oxygen and glucose and ii) create sufficient tissue ingrowth to anchor the implant and prevent motion artifact. On the other hand, inflammation is associated with invasion of tissue macrophages which have the ability to biodegrade many artificial biomaterials (some of which were, until recently, considered nonbiodegradable). When activated by a foreign body, tissue macrophages degranulate, releasing from their cytoplasmic myeloperoxidase system hypochlorite (bleach), H2O2 and other oxidant species. Both hypochlorite and H2O2 are known to break down a variety of polymers, including polyurethane, by a phenomenon referred to as environmental stress cracking. [Phillips et al., J. Biomat. Appl., 3:202-227 (1988); Stokes, J. Biomat. Appl. 3:228-259 (1988)]. Indeed, environmental stress cracking has been shown to limit the lifetime and performance of an enzyme-active polyurethane membrane stretched over the tip of a glucose sensor. [Updike et al., Am. Soc. Artificial Internal Organs, 40:157-163 (1994)].
Because both hypochlorite and H2O2 are short-lived chemical species in vivo, biodegradation will not occur if macrophages are kept a sufficient distance from the enzyme active membrane. The present invention contemplates the use of protective biomaterials of a few microns thickness or more (i.e., a bioprotective membrane) which are permeable to oxygen and glucose and are placed over the tip of the sensor to keep the macrophages from gaining proximity to the sensor membrane. The devices of the present invention are not limited by the nature of the bioprotective layer. However, the bioprotective layer should be biostable for long periods of time (e.g., several years); the present invention contemplates the use of polymers including, but not limited to, polypropylene, polysulphone, polytetrafluoroethylene (PTFE), and poly(ethylene terephthalate) (PET).
Preferably, the bioprotective layer is constructed of expanded PTFE with a pore size of about 0.2 μm to about 0.5 μm and a thickness of about 15 to about 35 μm. Most preferably, the bioprotective layer is constructed of expanded PTFE with a pore size of 0.4 μm and a thickness of approximately 25 μm (e.g., Millicell CM-Biopore®; Millipore).
C. The Enzyme Membrane
The present invention contemplates membranes impregnated with enzyme. It is not intended that the present invention be limited by the nature of the enzyme membrane. The enzyme membrane of a preferred embodiment is depicted in
There is a molar excess of glucose relative to the amount of oxygen in samples of blood. Indeed, for every free oxygen molecule in extracellular fluid, there are typically more than 100 glucose molecules present [Updike et al., Diabetes Care 5:207-21 (1982)]. However, an immobilized enzyme-based sensor using oxygen (O2) as cofactor must be supplied with oxygen in non-rate-limiting excess in order to respond linearly to changes in glucose concentration while not responding to changes in oxygen tension. More specifically, when a glucose-monitoring reaction is oxygen-limited, linearity is not achieved above minimal concentrations of glucose. Without a semipermeable membrane over the enzyme layer, linear response to glucose levels can be obtained only up to about 40 mg/dL; however, in a clinical setting, linear response to glucose levels are desirable up to at least about 500 mg/dL.
The resistance layer comprises a semipermeable membrane that controls the flux of oxygen and glucose to the underlying enzyme layer (i.e., limits the flux of glucose), rendering the necessary supply of oxygen in non-rate-limiting excess. As a result, the upper limit of linearity of glucose measurement is extended to a much higher value than that which could be achieved without the resistance layer. The devices of the present invention contemplate resistance layers comprising polymer membranes with oxygen-to-glucose permeability ratios of approximately 200:1; as a result, one-dimensional reactant diffusion is adequate to provide excess oxygen at all reasonable glucose and oxygen concentrations found in the subcutaneous matrix [Rhodes et al., Anal. Chem., 66:1520-1529 (1994)].
In preferred embodiments, the resistance layer has a thickness of less than about 45 μm, more preferably in the range of about 15 to about 40 μm and most preferably in the range of about 20 to about 35 μm.
In addition to glucose oxidase, the present invention contemplates the use of a membrane layer impregnated with other oxidases, e.g., galactose oxidase, uricase. For an enzyme-based electrochemical glucose sensor to perform well, the sensor's response must neither be limited by enzyme activity nor cofactor concentration. Because enzymes, including the very robust glucose oxidase, are subject to deactivation as a function of ambient conditions, this behavior needs to be accounted for in constructing sensors for long-term use.
The principle of losing half of the original enzyme activity in a specific time may be used in calculating how much enzyme needs to be included in the enzyme layer to provide a sensor of required lifetime (see Experimental section). Previously, researchers have found that, when placed in a saline solution at 37° C., glucose electrodes lose half of their electrode enzyme activity in 85 to 105 days [See, e.g., Tse and Gough, Biotechnol. Bioeng. 29:705-713 (1987)]. Under reasonable diabetic conditions and normal enzyme loading (e.g., 2×10−4 M glucose oxidase; see Example 4), useful sensor lifetimes can last for at least one year. However, exposure of the sensor to high levels of glucose in combination with low oxygen levels for prolonged periods can result in shortened sensor lifetimes. [Rhodes et al., Anal. Chem., 66:1520-1529 (1994)].
Excess glucose oxidase loading is required for long sensor life. The Experimental section provides a procedure that can be used to determine the appropriate amount of enzyme to be included in the enzyme layer. When excess glucose oxidase is used, up to two years of performance is possible from the glucose-monitoring devices contemplated by the present invention.
The interference layer comprises a thin, hydrophobic membrane that is non-swellable and has a low molecular weight cut-off. The interference layer is permeable to relatively low molecular weight substances, such as hydrogen peroxide, but restricts the passage of higher molecular weight substances, including glucose and ascorbic acid. The interference layer serves to allow analytes and other substances that are to be measured by the electrodes to pass through, while preventing passage of other substances.
The interference layer has a preferred thickness of less than about 5 μm, more preferably in the range of about 0.1 to about 5 μm and most preferably in the range of about 0.5 to about 3 μm.
To ensure electrochemical reaction, the electrolyte layer comprises a semipermeable coating that maintains hydrophilicity at the electrode region of the sensor interface. The electrolyte layer enhances the stability of the interference layer of the present invention by protecting and supporting the membrane that makes up the interference layer. Furthermore, the electrolyte layer assists in stabilizing operation of the device by overcoming electrode start-up problems and drifting problems caused by inadequate electrolyte. The buffered electrolyte solution contained in the electrolyte layer also protects against pH-mediated damage that may result from the formation of a large pH gradient between the hydrophobic interference layer and the electrode (or electrodes) due to the electrochemical activity of the electrode.
Preferably the coating comprises a flexible, water-swellable, substantially solid gel-like film having a “dry film” thickness of about 2.5 μm to about 12.5 μm, preferably about 6.0 μm. “Dry film” thickness refers to the thickness of a cured film cast from a coating formulation onto the surface of the membrane by standard coating techniques. The coating formulation comprises a premix of film-forming polymers and a crosslinking agent and is curable upon the application of moderate heat.
Suitable coatings are formed of a curable copolymer of a urethane polymer and a hydrophilic film-forming polymer. Particularly preferred coatings are formed of a polyurethane polymer having anionic carboxylate functional groups and non-ionic hydrophilic polyether segments, which is crosslinked in the present of polyvinylpyrrolidone and cured at a moderate temperature of about 50° C.
Particularly suitable for this purpose are aqueous dispersions of fully-reacted colloidal polyurethane polymers having cross-linkable carboxyl functionality (e.g., BAYBOND®; Mobay Corporation). These polymers are supplied in dispersion grades having a polycarbonate-polyurethane backbone containing carboxylate groups identified as XW-121 and XW-123; and a polyester-polyurethane backbone containing carboxylate groups, identified as XW-110-2. Particularly preferred is BAYBOND® 123, an aqueous anionic dispersion of an aliphate polycarbonate urethane polymer sold as a 35 weight percent solution in water and co-solvent N-methyl-2-pyrrolidone.
Polyvinylpyrrolidone is also particularly preferred as a hydrophilic water-soluble polymer and is available commercially in a range of viscosity grades and average molecular weights ranging from about 18,000 to about 500,000, under the PVP K® homopolymer series by BASF Wyandotte and by GAF Corporation. Particularly preferred is the homopolymer having an average molecular weight of about 360,000 identified as PVP-K90 (BASF Wyandotte). Also suitable are hydrophilic, film-forming copolymers of N-vinylpyrrolidone, such as a copolymer of N-vinylpyrrolidone and vinyl acetate, a copolymer of N-vinylpyrrolidone, ethylmethacrylate and methacrylic acid monomers, and the like.
The polyurethane polymer is crosslinked in the presence of the polyvinylpyrrolidone by preparing a premix of the polymers and adding a cross-linking agent just prior to the production of the membrane. Suitable cross-linking agents can be carbodiimides, epoxides and melamine/formaldehyde resins. Carbodiimide is preferred, and a preferred carbodiimide crosslinker is UCARLNK® XL-25 (Union Carbide).
The flexibility and hardness of the coating can be varied as desired by varying the dry weight solids of the components in the coating formulation. The term “dry weight solids” refers to the dry weight percent based on the total coating composition after the time the crosslinker is included. A preferred useful coating formulation can contain about 6 to about 20 dry weight percent, preferably about 8 dry weight percent, polyvinylpyrrolidone; about 3 to about 10 dry weight percent preferably about 5 dry weight percent cross-linking agent; and about 70 to about 91 weight percent, preferably about 87 weight percent of a polyurethane polymer, preferably a polycarbonate-polyurethane polymer. The reaction product of such a coating formulation is referred to herein as a water-swellable cross-linked matrix of polyurethane and polyvinylpyrrolidone.
D. The Electrolyte Phase
The electrolyte phase is a free-fluid phase comprising a solution containing at least one compound, usually a soluble chloride salt, that conducts electric current. The electrolyte phase flows over the electrodes (see
Generally speaking, the electrolyte phase should have the same or less osmotic pressure than the sample being analyzed. In preferred embodiments of the present invention, the electrolyte phase comprises normal saline.
E. Electrode
The electrode assembly of this invention may also be used in the manner commonly employed in the making of amperometric measurements. A sample of the fluid being analyzed is placed in contact with a reference electrode, e.g., silver/silver-chloride, and the electrode of this invention which is preferably formed of platinum. The electrodes are connected to a galvanometer or polarographic instrument and the current is read or recorded upon application of the desired D.C. bias voltage between the electrodes.
The ability of the present device electrode assembly to accurately measure the concentration of substances such as glucose over a broad range of concentrations in fluids including undiluted whole blood samples enables the rapid and accurate determination of the concentration of those substances. That information can be employed in the study and control of metabolic disorders including diabetes.
IV. Sensor Implantation and Radiotelemetric Output
Long-term sensor performance is best achieved, and transcutaneous bacterial infection is eliminated, with implanted devices capable of radiotelemetric output. The present invention contemplates the use of radiotelemetry to provide data regarding blood glucose levels, trends, and the like. The term “radiotelemetry” refers to the transmission by radio waves of the data recorded by the implanted device to an ex vivo recording station (e.g., a computer), where the data is recorded and, if desired, further processed.
Although totally implanted glucose sensors of three month lifetime, with radiotelemetric output, have been tested in animal models at intravenous sites [see, e.g. Armour et al., Diabetes, 39:1519-1526 (1990)], subcutaneous implantation is the preferred mode of implantation [see, e.g., Gilligan et al., Diabetes Care 17:882-887 (1994)]. The subcutaneous site has the advantage of lowering the risk for thrombophlebitis with hematogenous spread of infection and also lowers the risk of venous thrombosis with pulmonary embolism. In addition, subcutaneous placement is technically easier and more cost-effective than intravenous placement, as it may be performed under local anesthesia by a non-surgeon health care provider in an outpatient setting.
Preferably, the radiotelemetry devices contemplated for use in conjunction with the present invention possess features including small package size, adequate battery life, acceptable noise-free transmission range, freedom from electrical interference, and easy data collection and processing. Radiotelemetry provides several advantages, one of the most important of which is the ability of an implanted device to measure analyte levels in a sealed-off, sterile environment.
The present invention is not limited by the nature of the radiotelemetry equipment or methods for its use. Indeed, commercially available equipment can be modified for use with the devices of the present invention (e.g., devices manufactured by Data Sciences). Similarly, custom-designed radiotelemetry devices like those reported in the literature can be used in conjunction with the implantable analyte-measuring devices of the present invention [see, e.g., McKean and Gough, IEEE Trans. Biomed. Eng. 35:526-532 (1988); Shichiri et al., Diabetes Care 9:298-301 (1986); and Shults et al., IEEE Trans. Biomed. Eng. 41:937-942 (1994)]. In a preferred embodiment, transmitters are programmed with an external magnet to transmit at 4-, 32-, or 256-second intervals depending on the need of the subject; presently, battery lifetimes at the current longest transmission intervals (about 256 seconds) is approximately up to two years.
V. Response Time and Calibration
Every measurement method reports data with some delay after the measured event. For data to be useful, this delay must be smaller than some time depending on the needs of the method. Thus, response time of the current invention has been carefully studied. The use of the term “initial response” is not to be confused with the term “response time.” After a step function change in glucose concentration, the time delay before the first unequivocal change in sensor signal occurs is the “initial response,” while the following time delay to reach 90% of the steady-state signal development is the “response time.” “Response time” is the factor which normally controls how quickly a sensor can track a dynamically changing system.
Furthermore, the time required before a glucose sensor in a FBC will indicate an initial response to a bolus intravenous glucose injection is a function of the animal “circulation time” and the sensor's “initial response”. The circulation time is the time required for a bolus glucose injection to reach the site of sensor implantation.
Generally speaking, equilibration between vascular and interstitial compartments for glucose is so rapid that it plays no role in either the initial response or the observed response time. If the tip of the sensor is in intimate contact with the interstitial compartment (e.g., FBC), then there is no significant delay in glucose diffusing from the capillary lumen to the tip of the sensor. The inventors have found that the glucose sensors of the present invention provide initial responses of about 30 seconds in dogs about half of which is circulation time. The dog model represents a useful and accepted model for determining the efficacy of glucose monitoring devices.
While the devices of the present invention do not require a specific response time, in preferred embodiments of the present invention, the in vitro 90% response times at 37° C. for subsequently subcutaneously implanted devices are in the range of 2 to 5 minutes in dogs. Though the use of the devices of the present invention does not require an understanding of the factors that influence response time or the factors' mechanisms of action, in vivo response times are believed to be primarily a function of glucose diffusion through the sensor membrane (e.g., a 40-60 micron membrane). Of note, response times of up to about 10 minutes do not limit the clinical utility of tracking blood glucose in diabetic patients because physiologic or pathologic glucose levels do not change more rapidly than a few percent per minute.
In calibrating the glucose sensors of the present invention, a single point recalibration of the sensor at four-week intervals against an acceptable glucose reference method is preferred (e.g., calibration against blood obtained from a finger-prick). Generally speaking, the recalibration amounts to a simple adjustment in sensor gain. The sensor offset current (i.e., the current at 0 mg/dL glucose) needs to remain invariant over the duration of the implant for the sensor to provide optimal data.
The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
In the preceding description and the experimental disclosure which follows, the following abbreviations apply: Eq and Eqs (equivalents); mEq (milliequivalents); M (molar); mM (millimolar) μM (micromolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); μg (micrograms); Kg (kilograms); L (liters); mL (milliliters); dL (deciliters); μL (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); h and hr (hours); min. (minutes); s and sec. (seconds); ° C. (degrees Centigrade); Astor Wax (Titusville, Pa.); BASF Wyandotte Corporation (Parsippany, N.J.); Data Sciences, Inc. (St. Paul, Minn.); DuPont (DuPont Co., Wilmington, Del.); Exxon Chemical (Houston, Tex.); GAF Corporation (New York, N.Y.); Markwell Medical (Racine, Wis.); Meadox Medical, Inc. (Oakland, N.J.); Mobay (Mobay Corporation, Pittsburgh, Pa.); Sandoz (East Hanover, N.J.); and Union Carbide (Union Carbide Corporation; Chicago, Ill.).
The polyurethanes are preferably prepared as block copolymers by solution polymerization techniques as generally described in Lyman [J. Polymer Sci. 45:49 (1960)]. Specifically, a two-step solution polymerization technique is used in which the poly(oxyethylene) glycol is first “capped” by reaction with a diisocyanate to form a macrodiisocyanate. The macrodiisocyanate is then coupled with a diol (or diamine) and the diisocyanate to form a block copolyetherurethane (or a block copolyurethaneurea). The resulting block copolymers are tough and elastic and may be solution-cast in N,N-dimethylformamide to yield clear films that demonstrate good wet strength when swollen in water.
In particular, a mixture of 8.4 g (0.006 mol), poly(oxyethylene) glycol (CARBOWAX® 1540, Union Carbide), and 3.0 g (0.012 mol) 4,4′-diphenylmethane diisocyanate in 20 mL dimethyl sulfoxide/4-methyl-2-pentanone (50/50) is placed in a three-necked flask equipped with a stirrer and condenser and protected from moisture. The reaction mixture is stirred and heated at 110° C. for about one hour. To this clear solution is added 1.5 g (0.014 mol) 1,5-pentanediol and 2.0 g (0.008 mol) 4,4′-diphenylmethane diisocyanate.
After heating at 110° C. for an additional two hours, the resulting viscous solution is poured into water. The tough, rubbery, white polymer precipitate that forms is chopped in a Waring Blender, washed with water and dried in a vacuum oven at about 60° C. The yield is essentially quantitative. The inherent viscosity of the copolymer in N,N-dimethyl formamide is 0.59 at 30° C. (at a concentration of about 0.05 percent by weight).
As previously described, the electrolyte layer, the membrane layer closest to the electrode, can be coated as a water-swellable film. This example illustrates a coating comprising a polyurethane having anionic carboxylate functional groups and hydrophilic polyether groups and polyvinylpyrrolidone (PVP) that can be cross-linked by carbodiimide.
A coating preparation is prepared comprising a premix of a colloidal aqueous dispersion of particles of a urethane polymer having a polycarbonate-polyurethane (PC-PU) backbone containing carboxylate groups and the water-soluble hydrophilic polymer, PVP, which is crosslinked by the addition of the cross-linking agent just before production of the coated membrane. Example coating formulations are illustrated in Table 1.
1Aqueous solution containing 12.5 weight percent PVP prepared from polyvinylpyrrolidone having a number average molecular weight of about 360,000 sold as a powder under the trademark BASF K90 by BASF Wyandotte Corporation.
2Colloidal dispersion of a polycarbonatepolyurethane (PCPU) polymer at about 35 weight percent solids in a co-solvent mixture of about 53 weight percent water and about 12 weight percent N-methyl-2-pyrrolidone (BAYBOND ® 123 or XW123; Mobay Corporation). As supplied, the dispersion has a pH of about 7.5-9.0.
3Carbodiimide (UCARLNK ® XL25SE, Union Carbide Corporation) supplied at about 50 weight percent solids in a solvent solution of propylene glycol monomethylether acetate.
The viscosity and pH of the premix can be controlled and maintained during processing and to prolong its useful life by adding water or adjusting the pH with dilute ammonia solution or an equivalent base prior to adding the crosslinker.
For production, the coating is applied with a Mayer rod onto the unbound surface of a multilayered membrane. The amount of coating applied should cast a film having a “dry film” thickness of about 2.5 μm to about 12.5 μm, preferably about 6.0 μm. The coating is dried above room temperature preferably at about 50° C. This coating dries to a substantially solid gel-like film that is water swellable to maintain electrolyte between the membrane covering the electrode and the electrode in the electrode assembly during use.
The following procedure was used to determine the amount of enzyme to be included in the enzyme layer. It is to be understood that the present invention is not limited to the use of this or a similar procedure, but rather contemplates the use of other techniques known in the art.
A starting glucose oxidase concentration of 2×10−4 M was calculated from the enzyme weight and the final volume of the enzyme layer. Thereafter, a series of eight additional membrane formulations was prepared by decrementing enzyme concentration in 50% steps (referred to as a change of one “half loading”) down to 7.8×10−7 M. Sensor responses were then collected for this range of enzyme loadings and compared to computer-simulated sensor outputs. The simulation parameter set used included previously-determined membrane permeabilities and the literature mechanisms and kinetics for glucose oxidase. [Rhodes et al., Anal. Chem., 66:1520-1529 (1994)].
There was a good match of real-to-simulated sensor output at all loadings (data not shown). Approximately a six-to-seven “half loading” drop in enzyme activity was required before the sensor output dropped 10%; another two-to-three half loading drop in enzyme activity was required to drop the sensor response to 50% of the fully loaded sensor response. These results indicate that, at the loading used and the decay rates measured, up to two years of performance is possible from these sensors when the sensor does not see extended periods of high glucose and physiologically low O2 concentrations.
This example illustrates long-term glucose sensor device response following subcutaneous implantation of sensor devices contemplated by the present invention into a dog. The stages of FBC development are indicated by the long term glucose sensor device response.
The data set forth in
In addition to collecting normoglycemic or non-diabetic dog data from the sensor of the present invention as shown in Example 4, calibration stability, dynamic range, freedom from oxygen dependence, response time and linearity of the sensor can be studied by artificial manipulation of the intravenous glucose of the sensor host.
This was done in this example via infusion of a 15 g bolus of 50% sterile Dextrose given intravenously in less than about 20 seconds. Reference blood glucose data was then taken from a different vein at 2-5 minute intervals for up to 2 hours after bolus infusion.
As with any analytical system, periodic calibration should be performed with the devices of the present invention. Thus, the present invention contemplates some interval of calibration and/or control testing to meet analytical, clinical and regulatory requirements.
This example describes experiments directed at sensor accuracy and long-term glucose sensor response of several sensor devices contemplated by the present invention.
In vitro testing of the sensor devices was accomplished in a manner similar to that previously described. [Gilligan et al., Diabetes Care 17:882-887 (1994)]. Briefly, sensor performance was verified by demonstrating linearity to 100 mg/dL glucose concentration steps from 0 mg/dL through 400 mg/dL (22 mM) with a 90% time response to the glucose steps of less than 5 minutes. A typical satisfactory response to this protocol is shown in
Six sensor devices meeting the parameters described above were surgically implanted under general anesthesia (pentothal induction to effect, followed by halothane maintenance) into the paravertebral subcutaneous tissue of the same mongrel non-diabetic dog. A two-inch skin incision was made several inches from the spine for each implant allowing the creation of a tight-fitting subcutaneous pouch by blunt dissection. The implant was then inserted into the pouch in sensor-down configuration. Subcutaneous tissue was then closed with 3-0 vicryl and skin with 2-0 nylon. Animals were closely monitored for discomfort after surgery and analgesics administered if necessary.
These sensor devices were implanted two-at-a-time in the same dog at approximately six week intervals. Four of the sensor devices were covered with a PTFE-comprising angiogenic layer (these sensor devices were designated Sensors 1901, 1902, 1903, and 1905), while two of the sensor devices served as control sensor devices and did not contain an angiogenic layer, i.e., they contained a bioprotective membrane and the underlying sensor interface structures, as previously described (these sensor devices were designated Sensors 1904 and 1906). To insure anchoring of the device into the subcutaneous tissue, the sensor-side of each implant, except for just over the tip of the sensor, was jacketed in surgical grade double velour polyester fabric (Meadox Medical, Inc.). All sensor devices were tracked after implantation at four-minute intervals using radiotelemetry to follow the long-term sensor response to normoglycemia, allowing verification of the long-term stability of the sensors. To screen for sensor response to changing glucose on selected days following implantation, the response to 0.5 mg glucagon administered subcutaneously was assessed. Responding sensors were identified by a characteristically stable signal prior to glucagon administration followed by a substantial increase in signal within 20 minutes of glucagon injection. The sensor transients then reversed and returned to the prior signal levels within one hour after glucagon injection.
To determine in vivo sensor response times, short-term stability, linearity to glucose concentration, and possible oxygen cofactor limitation effects, glucose infusion studies of up to five hours duration were performed on the dog. These studies were run approximately once every three weeks. The dog was pretrained to rest comfortably and was fully alert during this testing. These experiments used the somatostatin analog octreotide (SANDOSTATIN®, Sandoz) to inhibit the release of insulin, allowing for a slow ramping of blood glucose to the 400-500 mg/dL concentration range.
Sensors were monitored at 32-second intervals to allow simultaneous tracking of up to six sensor devices. In this protocol, octreotide was injected (36-50 μg/kg) 15-20 minutes before initiation of the glucose infusion. Two peripheral veins were cannulated in the dog to allow for glucose infusion and blood glucose sampling. Ten percent dextrose (0.55 mM) was continuously infused at gradually increasing rates to provide smooth increases in blood glucose from the approximate fasting glucose concentration of about 100 mg/dL to greater than 400 mg/dL. This infusion protocol provides sensor glucose concentration data which can be correlated with reference plasma glucose values when blood samples were drawn from the animal every 5-to-10 minutes. The primary reference glucose determinations were made using a hexokinase method on the DuPont Dimension AR®. A DIRECT 30/30® meter (Markwell Medical) was also used during the course of the experiment to serve as a secondary monitor for the reference blood glucose values and estimate when 400 mg/dL had been reached. At this point the glucose infusion pump was turned off and the blood glucose allowed to return to its normal level.
An additional variation of the protocol described above involved studying the effects of insulin administration on blood glucose concentration prior to the octreotide injection. For these studies 5 units of insulin were injected intravenously, the blood glucose tracked down to 40 mg/dl with the DIRECT 30/30® (Markwell Medical), the octreotide injection made as before, and the infusion pump then started. While the initial glucose pump rate was the same, it was increased faster than before to counteract the insulin and to maintain the same experimental timing.
Once studies were completed, the data was initially analyzed using the final in vitro sensor calibration factors to calculate the implanted sensor glucose concentration. If changes were needed in these factors to optimize the linear regression of sensor to reference blood glucose they were made and noted and followed over the lifetime of the sensor device.
At varying points in time, the implanted sensor devices became less than optimal and were then explanted to determine the underlying cause (less than optimal was defined as the inability to accurately track glucose infusion during two successive tests). Explantation surgical protocols were very similar to those used in the implantation procedure except that the foreign body capsule was opened around the perimeter of the oval implant. The back and sides of the housing had no tissue attachment (as they were not covered with polyester velour), and thus easily separated from the surrounding tissue. The top of the sensor device with attached capsule was then carefully cut free from the subcutaneous tissues.
Once explanted, the sensor devices were carefully examined under a dissecting microscope to look at the state of the capsule tissue contacting the sensor membranes. Once this had been characterized and documented, the tissue was carefully removed from the membrane surface and saved for histological examination. If sensor visualization demonstrated intact membrane layers an initial in vitro calibration check was performed. The sensors were then disassembled from the top membrane down (i.e., from the membrane furthest from the electrodes) with a glucose and hydrogen peroxide calibration check made after removal of each layer. This allowed differentiation of the mechanisms leading to less than optimal results in the membranes and determination of whether processes such as environmental stress cracking, biofouling, or loss of enzyme activity were occurring.
Typical Glucose Infusion Studies: The six sensor devices were tracked for 20-150 days and were evaluated using the octreotide-glucose infusion protocol.
Angiogenesis Stimulating Membrane Sensors vs. Control Membrane Sensors: Generally speaking, demonstration of improvement in a sensor can be judged by noting whether significant improvements in sensor start up time, increased yields of operating glucose sensors, extension of sensor lifetimes, and maintenance of calibration factors occurs. The lifetime of a glucose sensor can be defined as the time of first glucose sensing (in this case during a glucagon challenge) to the last glucose infusion study which provides correct glucose trends to concentration changes. All sensors showed glucose tracking and only one sensor showed a duration of less than 10 days. Average sensor lifetimes of 84±55 days were observed with the sensors containing the angiogenesis-stimulating membrane, values superior to the control sensors which only showed lifetimes of 35±10 days. In addition, one of the sensors incorporating the angiogenic membrane provided optimal data to 150 days.
The description and experimental materials presented above are intended to be illustrative of the present invention while not limiting the scope thereof. It will be apparent to those skilled in the art that variations and modifications can be made without departing from the spirit and scope of the present invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2830020 | Christmann et al. | Apr 1958 | A |
| 3220960 | Drahoslav Lim et al. | Nov 1965 | A |
| 3381371 | Russell | May 1968 | A |
| 3562352 | Nyilas | Feb 1971 | A |
| 3607329 | Manjikian | Sep 1971 | A |
| 3746588 | Brown, Jr. | Jul 1973 | A |
| 3775182 | Patton et al. | Nov 1973 | A |
| 3791871 | Rowley | Feb 1974 | A |
| 3838033 | Mindt et al. | Sep 1974 | A |
| 3898984 | Mandel et al. | Aug 1975 | A |
| 3943918 | Lewis | Mar 1976 | A |
| 4136250 | Mueller et al. | Jan 1979 | A |
| 4197840 | Beck et al. | Apr 1980 | A |
| 4225410 | Pace | Sep 1980 | A |
| 4240889 | Yoda et al. | Dec 1980 | A |
| 4253469 | Aslan | Mar 1981 | A |
| 4255500 | Hooke | Mar 1981 | A |
| 4256561 | Schindler et al. | Mar 1981 | A |
| 4260725 | Keogh et al. | Apr 1981 | A |
| 4267145 | Wysong | May 1981 | A |
| 4292423 | Kaufmann et al. | Sep 1981 | A |
| 4324257 | Albarda et al. | Apr 1982 | A |
| 4353888 | Sefton | Oct 1982 | A |
| 4374013 | Enfors | Feb 1983 | A |
| 4403984 | Ash et al. | Sep 1983 | A |
| 4415666 | D'Orazio et al. | Nov 1983 | A |
| 4418148 | Oberhardt | Nov 1983 | A |
| 4431004 | Bessman et al. | Feb 1984 | A |
| 4431507 | Nankai et al. | Feb 1984 | A |
| 4436094 | Cerami | Mar 1984 | A |
| 4442841 | Uehara et al. | Apr 1984 | A |
| 4454295 | Wittmann et al. | Jun 1984 | A |
| 4477314 | Richter et al. | Oct 1984 | A |
| 4482666 | Reeves | Nov 1984 | A |
| 4484987 | Gough | Nov 1984 | A |
| 4493714 | Ueda et al. | Jan 1985 | A |
| 4494950 | Fischell | Jan 1985 | A |
| RE31916 | Oswin et al. | Jun 1985 | E |
| 4527999 | Lee | Jul 1985 | A |
| 4545382 | Higgins et al. | Oct 1985 | A |
| 4554927 | Fussell | Nov 1985 | A |
| 4571292 | Liu et al. | Feb 1986 | A |
| 4602922 | Cabasso et al. | Jul 1986 | A |
| 4632968 | Yokota et al. | Dec 1986 | A |
| 4644046 | Yamada | Feb 1987 | A |
| 4647643 | Zdrabala et al. | Mar 1987 | A |
| 4650547 | Gough | Mar 1987 | A |
| 4655880 | Liu | Apr 1987 | A |
| 4671288 | Gough | Jun 1987 | A |
| 4672970 | Uchida et al. | Jun 1987 | A |
| 4680268 | Clark, Jr. | Jul 1987 | A |
| 4684538 | Klemarczyk | Aug 1987 | A |
| 4685463 | Williams | Aug 1987 | A |
| 4686044 | Behnke et al. | Aug 1987 | A |
| 4686137 | Ward, Jr. et al. | Aug 1987 | A |
| 4689149 | Kanno et al. | Aug 1987 | A |
| 4703756 | Gough et al. | Nov 1987 | A |
| 4711245 | Higgins | Dec 1987 | A |
| 4721677 | Clark | Jan 1988 | A |
| 4726381 | Jones | Feb 1988 | A |
| 4731726 | Allen | Mar 1988 | A |
| 4739380 | Lauks et al. | Apr 1988 | A |
| 4750496 | Reinhart et al. | Jun 1988 | A |
| 4757022 | Shults et al. | Jul 1988 | A |
| 4759828 | Young et al. | Jul 1988 | A |
| 4763658 | Jones | Aug 1988 | A |
| 4781733 | Babcock et al. | Nov 1988 | A |
| 4786657 | Hammar et al. | Nov 1988 | A |
| 4787398 | Garcia et al. | Nov 1988 | A |
| 4793555 | Lee et al. | Dec 1988 | A |
| 4795542 | Ross et al. | Jan 1989 | A |
| 4803243 | Fujimoto et al. | Feb 1989 | A |
| 4805624 | Yao et al. | Feb 1989 | A |
| 4805625 | Wyler | Feb 1989 | A |
| 4813424 | Wilkins | Mar 1989 | A |
| 4822336 | DiTraglia | Apr 1989 | A |
| 4823808 | Clegg et al. | Apr 1989 | A |
| 4832034 | Pizziconi | May 1989 | A |
| 4852573 | Kennedy | Aug 1989 | A |
| 4861830 | Ward, Jr. | Aug 1989 | A |
| 4871440 | Nagata et al. | Oct 1989 | A |
| 4880883 | Grasel et al. | Nov 1989 | A |
| 4883057 | Broderick | Nov 1989 | A |
| 4886740 | Vadgama | Dec 1989 | A |
| 4890620 | Gough | Jan 1990 | A |
| 4890621 | Hakky | Jan 1990 | A |
| 4902294 | Gosserez | Feb 1990 | A |
| 4908208 | Lee et al. | Mar 1990 | A |
| 4909908 | Ross et al. | Mar 1990 | A |
| 4919141 | Zier et al. | Apr 1990 | A |
| 4927407 | Dorman | May 1990 | A |
| 4938860 | Wogoman | Jul 1990 | A |
| 4951657 | Pfister et al. | Aug 1990 | A |
| 4952618 | Olsen | Aug 1990 | A |
| 4953552 | DeMarzo | Sep 1990 | A |
| 4954381 | Cabasso et al. | Sep 1990 | A |
| 4960594 | Honeycutt | Oct 1990 | A |
| 4961954 | Goldberg et al. | Oct 1990 | A |
| 4970145 | Bennetto et al. | Nov 1990 | A |
| 4973320 | Brenner et al. | Nov 1990 | A |
| 4986271 | Wilkins | Jan 1991 | A |
| 4988341 | Columbus et al. | Jan 1991 | A |
| 4992794 | Brouwers | Feb 1991 | A |
| 4994167 | Shults et al. | Feb 1991 | A |
| 5002590 | Friesen et al. | Mar 1991 | A |
| 5010141 | Mueller | Apr 1991 | A |
| 5034112 | Murase et al. | Jul 1991 | A |
| 5034461 | Lai et al. | Jul 1991 | A |
| 5045601 | Capelli et al. | Sep 1991 | A |
| 5050612 | Matsumura | Sep 1991 | A |
| 5063081 | Cozzette et al. | Nov 1991 | A |
| 5070169 | Robertson et al. | Dec 1991 | A |
| 5071452 | Avrillon et al. | Dec 1991 | A |
| 5089112 | Skotheim et al. | Feb 1992 | A |
| 5094876 | Goldberg et al. | Mar 1992 | A |
| 5100689 | Goldberg et al. | Mar 1992 | A |
| 5108819 | Heller et al. | Apr 1992 | A |
| 5115056 | Mueller et al. | May 1992 | A |
| 5120813 | Ward, Jr. | Jun 1992 | A |
| 5128408 | Tanaka et al. | Jul 1992 | A |
| 5130231 | Kennedy et al. | Jul 1992 | A |
| 5135297 | Valint et al. | Aug 1992 | A |
| 5137028 | Nishimura | Aug 1992 | A |
| 5147725 | Pinchuk | Sep 1992 | A |
| 5155149 | Atwater et al. | Oct 1992 | A |
| 5160418 | Mullen | Nov 1992 | A |
| 5165407 | Wilson et al. | Nov 1992 | A |
| 5169906 | Cray et al. | Dec 1992 | A |
| 5171689 | Kawaguri et al. | Dec 1992 | A |
| 5183549 | Joseph et al. | Feb 1993 | A |
| 5190041 | Palti | Mar 1993 | A |
| 5200051 | Cozzette et al. | Apr 1993 | A |
| 5202261 | Musho et al. | Apr 1993 | A |
| 5208313 | Krishnan | May 1993 | A |
| 5212050 | Mier et al. | May 1993 | A |
| 5219965 | Valint et al. | Jun 1993 | A |
| 5221724 | Li et al. | Jun 1993 | A |
| 5222980 | Gealow | Jun 1993 | A |
| 5242835 | Jensen | Sep 1993 | A |
| 5249576 | Golberger et al. | Oct 1993 | A |
| 5250439 | Musho et al. | Oct 1993 | A |
| 5262305 | Heller et al. | Nov 1993 | A |
| 5264104 | Gregg et al. | Nov 1993 | A |
| 5269891 | Colin | Dec 1993 | A |
| 5282848 | Schmitt | Feb 1994 | A |
| 5284140 | Allen et al. | Feb 1994 | A |
| 5286364 | Yacynych et al. | Feb 1994 | A |
| 5296144 | Sternina et al. | Mar 1994 | A |
| 5298144 | Spokane | Mar 1994 | A |
| 5299571 | Mastrototaro | Apr 1994 | A |
| 5310469 | Cunningham et al. | May 1994 | A |
| 5314471 | Brauker et al. | May 1994 | A |
| 5316008 | Suga et al. | May 1994 | A |
| 5321414 | Alden et al. | Jun 1994 | A |
| 5322063 | Allen et al. | Jun 1994 | A |
| 5324322 | Grill et al. | Jun 1994 | A |
| 5331555 | Hashimoto et al. | Jul 1994 | A |
| 5334681 | Mueller et al. | Aug 1994 | A |
| 5337747 | Neftel | Aug 1994 | A |
| 5342693 | Winters et al. | Aug 1994 | A |
| 5344454 | Clarke et al. | Sep 1994 | A |
| 5352348 | Young et al. | Oct 1994 | A |
| 5352351 | White | Oct 1994 | A |
| 5368028 | Palti | Nov 1994 | A |
| 5372133 | Hogen Esch | Dec 1994 | A |
| 5376400 | Goldberg et al. | Dec 1994 | A |
| 5380536 | Hubbell et al. | Jan 1995 | A |
| 5384028 | Ito | Jan 1995 | A |
| 5387327 | Khan | Feb 1995 | A |
| 5390671 | Lord et al. | Feb 1995 | A |
| 5391250 | Cheney, II et al. | Feb 1995 | A |
| 5397451 | Senda et al. | Mar 1995 | A |
| 5411647 | Johnson et al. | May 1995 | A |
| 5411866 | Luong | May 1995 | A |
| 5417395 | Fowler et al. | May 1995 | A |
| 5421923 | Clarke et al. | Jun 1995 | A |
| 5426158 | Mueller et al. | Jun 1995 | A |
| 5428123 | Ward et al. | Jun 1995 | A |
| 5429735 | Johnson et al. | Jul 1995 | A |
| 5431160 | Wilkins | Jul 1995 | A |
| 5438984 | Schoendorfer | Aug 1995 | A |
| 5453278 | Chan et al. | Sep 1995 | A |
| 5458631 | Xavier et al. | Oct 1995 | A |
| 5462051 | Oka et al. | Oct 1995 | A |
| 5462064 | D'Angelo et al. | Oct 1995 | A |
| 5462645 | Albery et al. | Oct 1995 | A |
| 5466356 | Schneider et al. | Nov 1995 | A |
| 5466575 | Cozzette et al. | Nov 1995 | A |
| 5469846 | Khan | Nov 1995 | A |
| 5476094 | Allen et al. | Dec 1995 | A |
| 5480711 | Ruefer | Jan 1996 | A |
| 5482008 | Stafford et al. | Jan 1996 | A |
| 5494562 | Maley et al. | Feb 1996 | A |
| 5497772 | Schulman et al. | Mar 1996 | A |
| 5507288 | Bocker et al. | Apr 1996 | A |
| 5508509 | Yafuso et al. | Apr 1996 | A |
| 5513636 | Palti | May 1996 | A |
| 5518601 | Foos et al. | May 1996 | A |
| 5521273 | Yilgor et al. | May 1996 | A |
| 5529066 | Palti | Jun 1996 | A |
| 5531878 | Vadgama et al. | Jul 1996 | A |
| 5538511 | Van Antwerp | Jul 1996 | A |
| 5541305 | Yokota et al. | Jul 1996 | A |
| 5545223 | Neuenfeldt et al. | Aug 1996 | A |
| 5549675 | Neuenfeldt et al. | Aug 1996 | A |
| 5552112 | Schiffmann | Sep 1996 | A |
| 5554339 | Cozzette | Sep 1996 | A |
| 5564439 | Picha | Oct 1996 | A |
| 5568806 | Cheney, II et al. | Oct 1996 | A |
| 5569186 | Lord et al. | Oct 1996 | A |
| 5569462 | Martinson et al. | Oct 1996 | A |
| 5571395 | Park et al. | Nov 1996 | A |
| 5575930 | Tietje-Girault et al. | Nov 1996 | A |
| 5578463 | Berka et al. | Nov 1996 | A |
| 5582184 | Ericson et al. | Dec 1996 | A |
| 5582697 | Ikeda et al. | Dec 1996 | A |
| 5584813 | Livingston et al. | Dec 1996 | A |
| 5584876 | Bruchman et al. | Dec 1996 | A |
| 5586553 | Halili et al. | Dec 1996 | A |
| 5589133 | Suzuki | Dec 1996 | A |
| 5589563 | Ward et al. | Dec 1996 | A |
| 5593440 | Brauker et al. | Jan 1997 | A |
| 5593852 | Heller et al. | Jan 1997 | A |
| 5607565 | Azarnia et al. | Mar 1997 | A |
| 5611900 | Worden | Mar 1997 | A |
| 5624537 | Turner et al. | Apr 1997 | A |
| 5628890 | Carter et al. | May 1997 | A |
| 5640954 | Pfeiffer | Jun 1997 | A |
| 5653756 | Clarke et al. | Aug 1997 | A |
| 5653863 | Genshaw et al. | Aug 1997 | A |
| 5660163 | Schulman et al. | Aug 1997 | A |
| 5665222 | Heller et al. | Sep 1997 | A |
| 5670097 | Duan et al. | Sep 1997 | A |
| 5686829 | Girault | Nov 1997 | A |
| 5695623 | Michel et al. | Dec 1997 | A |
| 5700559 | Sheu et al. | Dec 1997 | A |
| 5703359 | Wampler, III | Dec 1997 | A |
| 5704354 | Priedel et al. | Jan 1998 | A |
| 5706807 | Picha | Jan 1998 | A |
| 5711861 | Ward et al. | Jan 1998 | A |
| 5713888 | Neuenfeldt et al. | Feb 1998 | A |
| 5733336 | Neuenfeldt et al. | Mar 1998 | A |
| 5735273 | Kurnik et al. | Apr 1998 | A |
| 5741330 | Brauker et al. | Apr 1998 | A |
| 5743262 | Lepper, Jr. et al. | Apr 1998 | A |
| 5746898 | Priedel | May 1998 | A |
| 5756632 | Ward et al. | May 1998 | A |
| 5760155 | Mowrer et al. | Jun 1998 | A |
| 5766839 | Johnson et al. | Jun 1998 | A |
| 5776324 | Usala | Jul 1998 | A |
| 5777060 | Van Antwerp | Jul 1998 | A |
| 5782912 | Brauker et al. | Jul 1998 | A |
| 5786439 | Van Antwerp et al. | Jul 1998 | A |
| 5791344 | Schulman et al. | Aug 1998 | A |
| 5795453 | Gilmartin | Aug 1998 | A |
| 5800420 | Gross | Sep 1998 | A |
| 5800529 | Brauker et al. | Sep 1998 | A |
| 5804048 | Wong et al. | Sep 1998 | A |
| 5807375 | Gross et al. | Sep 1998 | A |
| 5807406 | Brauker et al. | Sep 1998 | A |
| 5807636 | Sheu et al. | Sep 1998 | A |
| 5820570 | Erickson | Oct 1998 | A |
| 5820622 | Gross et al. | Oct 1998 | A |
| 5833603 | Kovacs et al. | Nov 1998 | A |
| 5834583 | Hancock et al. | Nov 1998 | A |
| 5837377 | Sheu et al. | Nov 1998 | A |
| 5837454 | Cozzette et al. | Nov 1998 | A |
| 5837661 | Evans et al. | Nov 1998 | A |
| 5837728 | Purcell | Nov 1998 | A |
| 5840148 | Campbell et al. | Nov 1998 | A |
| 5843069 | Butler et al. | Dec 1998 | A |
| 5863400 | Drummond et al. | Jan 1999 | A |
| 5863972 | Beckelmann et al. | Jan 1999 | A |
| 5882354 | Brauker et al. | Mar 1999 | A |
| 5882494 | Van Antwerp | Mar 1999 | A |
| 5885566 | Goldberg | Mar 1999 | A |
| 5895235 | Droz | Apr 1999 | A |
| 5897955 | Drumheller | Apr 1999 | A |
| 5914026 | Blubaugh, Jr. et al. | Jun 1999 | A |
| 5914182 | Drumheller | Jun 1999 | A |
| 5931814 | Alex et al. | Aug 1999 | A |
| 5932299 | Katoot | Aug 1999 | A |
| 5944661 | Swette et al. | Aug 1999 | A |
| 5945498 | Hopken et al. | Aug 1999 | A |
| 5947127 | Tsugaya et al. | Sep 1999 | A |
| 5954643 | Van Antwerp et al. | Sep 1999 | A |
| 5955066 | Sako et al. | Sep 1999 | A |
| 5957854 | Besson et al. | Sep 1999 | A |
| 5959191 | Lewis et al. | Sep 1999 | A |
| 5961451 | Reber et al. | Oct 1999 | A |
| 5963132 | Yoakum | Oct 1999 | A |
| 5964261 | Neuenfeldt et al. | Oct 1999 | A |
| 5964993 | Blubaugh et al. | Oct 1999 | A |
| 5965380 | Heller et al. | Oct 1999 | A |
| 5967986 | Cimochowski et al. | Oct 1999 | A |
| 5969076 | Lai et al. | Oct 1999 | A |
| 5972199 | Heller | Oct 1999 | A |
| 5977241 | Koloski et al. | Nov 1999 | A |
| 5985129 | Gough et al. | Nov 1999 | A |
| 5989409 | Kurnik et al. | Nov 1999 | A |
| 6001067 | Shults et al. | Dec 1999 | A |
| 6002954 | Van Antwerp et al. | Dec 1999 | A |
| 6007845 | Domb | Dec 1999 | A |
| 6011984 | Van Antwerp et al. | Jan 2000 | A |
| 6013113 | Mika | Jan 2000 | A |
| 6018013 | Yoshida et al. | Jan 2000 | A |
| 6018033 | Chen et al. | Jan 2000 | A |
| 6022463 | Leader et al. | Feb 2000 | A |
| 6030827 | Davis et al. | Feb 2000 | A |
| 6039913 | Hirt et al. | Mar 2000 | A |
| 6043328 | Domschke et al. | Mar 2000 | A |
| 6049727 | Crothall | Apr 2000 | A |
| 6051389 | Ahl et al. | Apr 2000 | A |
| 6059946 | Yukawa et al. | May 2000 | A |
| 6066083 | Slater et al. | May 2000 | A |
| 6066448 | Wohlstadter et al. | May 2000 | A |
| 6071406 | Tsou | Jun 2000 | A |
| 6074775 | Gartstein et al. | Jun 2000 | A |
| 6081736 | Colvin et al. | Jun 2000 | A |
| 6083710 | Heller et al. | Jul 2000 | A |
| 6088608 | Schulman et al. | Jul 2000 | A |
| 6091975 | Daddona et al. | Jul 2000 | A |
| 6093172 | Funderburk et al. | Jul 2000 | A |
| 6117290 | Say | Sep 2000 | A |
| 6119028 | Schulman et al. | Sep 2000 | A |
| 6121009 | Heller et al. | Sep 2000 | A |
| 6122536 | Sun et al. | Sep 2000 | A |
| 6134461 | Say et al. | Oct 2000 | A |
| 6144871 | Saito et al. | Nov 2000 | A |
| 6162611 | Heller et al. | Dec 2000 | A |
| 6175752 | Say et al. | Jan 2001 | B1 |
| 6200772 | Vadgama et al. | Mar 2001 | B1 |
| 6208894 | Schulman et al. | Mar 2001 | B1 |
| 6212416 | Ward et al. | Apr 2001 | B1 |
| 6233471 | Berner et al. | May 2001 | B1 |
| 6248067 | Causey, III et al. | Jun 2001 | B1 |
| 6256522 | Schultz | Jul 2001 | B1 |
| 6259937 | Schulman et al. | Jul 2001 | B1 |
| 6264825 | Blackburn et al. | Jul 2001 | B1 |
| 6268161 | Han et al. | Jul 2001 | B1 |
| 6271332 | Lohmann et al. | Aug 2001 | B1 |
| 6275717 | Gross et al. | Aug 2001 | B1 |
| 6284478 | Heller et al. | Sep 2001 | B1 |
| 6285897 | Kilcoyne et al. | Sep 2001 | B1 |
| 6294281 | Heller | Sep 2001 | B1 |
| 6296615 | Brockway et al. | Oct 2001 | B1 |
| 6300002 | Webb et al. | Oct 2001 | B1 |
| 6303670 | Fujino et al. | Oct 2001 | B1 |
| 6306594 | Cozzette | Oct 2001 | B1 |
| 6309351 | Kurnik et al. | Oct 2001 | B1 |
| 6309526 | Fujiwara et al. | Oct 2001 | B1 |
| 6312706 | Lai et al. | Nov 2001 | B1 |
| 6325979 | Hahn et al. | Dec 2001 | B1 |
| 6329161 | Heller et al. | Dec 2001 | B1 |
| 6329488 | Terry et al. | Dec 2001 | B1 |
| 6330464 | Colvin, Jr. et al. | Dec 2001 | B1 |
| 6343225 | Clark, Jr. | Jan 2002 | B1 |
| 6358557 | Wang et al. | Mar 2002 | B1 |
| 6360888 | Melver et al. | Mar 2002 | B1 |
| 6366794 | Moussy et al. | Apr 2002 | B1 |
| 6368274 | Van Antwerp et al. | Apr 2002 | B1 |
| 6368658 | Schwarz et al. | Apr 2002 | B1 |
| 6387379 | Goldberg et al. | May 2002 | B1 |
| 6400974 | Lesho | Jun 2002 | B1 |
| 6406066 | Uegane | Jun 2002 | B1 |
| 6407195 | Sherman et al. | Jun 2002 | B2 |
| 6409674 | Brockway et al. | Jun 2002 | B1 |
| 6413393 | Van Antwerp et al. | Jul 2002 | B1 |
| 6424847 | Mastrototaro et al. | Jul 2002 | B1 |
| 6442413 | Silver | Aug 2002 | B1 |
| 6447448 | Ishikawa et al. | Sep 2002 | B1 |
| 6454710 | Ballerstadt et al. | Sep 2002 | B1 |
| 6461496 | Feldman et al. | Oct 2002 | B1 |
| 6466810 | Ward et al. | Oct 2002 | B1 |
| 6484046 | Say et al. | Nov 2002 | B1 |
| 6497729 | Moussy et al. | Dec 2002 | B1 |
| 6512939 | Colvin et al. | Jan 2003 | B1 |
| 6514718 | Heller et al. | Feb 2003 | B2 |
| 6528584 | Kennedy et al. | Mar 2003 | B2 |
| 6534711 | Pollack | Mar 2003 | B1 |
| 6546268 | Ishikawa et al. | Apr 2003 | B1 |
| 6547839 | Zhang et al. | Apr 2003 | B2 |
| 6551496 | Moles et al. | Apr 2003 | B1 |
| 6554982 | Shin et al. | Apr 2003 | B1 |
| 6558320 | Causey et al. | May 2003 | B1 |
| 6565509 | Say et al. | May 2003 | B1 |
| 6569309 | Otsuka et al. | May 2003 | B2 |
| 6579498 | Eglise | Jun 2003 | B1 |
| 6587705 | Kim et al. | Jul 2003 | B1 |
| 6591125 | Buse et al. | Jul 2003 | B1 |
| 6596294 | Lai et al. | Jul 2003 | B2 |
| 6613379 | Ward et al. | Sep 2003 | B2 |
| 6618934 | Feldman et al. | Sep 2003 | B1 |
| 6633772 | Ford et al. | Oct 2003 | B2 |
| 6642015 | Vachon et al. | Nov 2003 | B2 |
| 6654625 | Say et al. | Nov 2003 | B1 |
| 6670115 | Zhang | Dec 2003 | B1 |
| 6689265 | Heller et al. | Feb 2004 | B2 |
| 6692528 | Ward et al. | Feb 2004 | B2 |
| 6699383 | Lemire et al. | Mar 2004 | B2 |
| 6702857 | Brauker et al. | Mar 2004 | B2 |
| 6702972 | Markle | Mar 2004 | B1 |
| 6721587 | Gough | Apr 2004 | B2 |
| 6737158 | Thompson | May 2004 | B1 |
| 6741877 | Shults et al. | May 2004 | B1 |
| 6773565 | Kunimoto et al. | Aug 2004 | B2 |
| 6784274 | van Antwerp et al. | Aug 2004 | B2 |
| 6789634 | Denton | Sep 2004 | B1 |
| 6793632 | Sohrab | Sep 2004 | B2 |
| 6793789 | Choi et al. | Sep 2004 | B2 |
| 6793802 | Lee et al. | Sep 2004 | B2 |
| 6801041 | Karinka et al. | Oct 2004 | B2 |
| 6802957 | Jung et al. | Oct 2004 | B2 |
| 6804544 | van Antwerp et al. | Oct 2004 | B2 |
| 6858218 | Lai et al. | Feb 2005 | B2 |
| 6862465 | Shults et al. | Mar 2005 | B2 |
| 6867262 | Angel et al. | Mar 2005 | B1 |
| 6881551 | Heller et al. | Apr 2005 | B2 |
| 6895263 | Shin et al. | May 2005 | B2 |
| 6895265 | Silver | May 2005 | B2 |
| 6908681 | Terry et al. | Jun 2005 | B2 |
| 6932894 | Mao et al. | Aug 2005 | B2 |
| 6952604 | DeNuzzio et al. | Oct 2005 | B2 |
| 6965791 | Hitchcock et al. | Nov 2005 | B1 |
| 6969451 | Shin et al. | Nov 2005 | B2 |
| 6972080 | Tomioka et al. | Dec 2005 | B1 |
| 6973706 | Say et al. | Dec 2005 | B2 |
| 7008979 | Schottman et al. | Mar 2006 | B2 |
| 7014948 | Lee et al. | Mar 2006 | B2 |
| 7033322 | Silver | Apr 2006 | B2 |
| 7052131 | McCabe et al. | May 2006 | B2 |
| 7058437 | Buse et al. | Jun 2006 | B2 |
| 7074307 | Simpson et al. | Jul 2006 | B2 |
| 7081195 | Simpson et al. | Jul 2006 | B2 |
| 7108778 | Simpson et al. | Sep 2006 | B2 |
| 7110803 | Shults et al. | Sep 2006 | B2 |
| 7115884 | Walt et al. | Oct 2006 | B1 |
| 7118667 | Lee | Oct 2006 | B2 |
| 7120483 | Russell et al. | Oct 2006 | B2 |
| 7134999 | Brauker et al. | Nov 2006 | B2 |
| 7136689 | Shults et al. | Nov 2006 | B2 |
| 7153265 | Vachon | Dec 2006 | B2 |
| 7157528 | Ward | Jan 2007 | B2 |
| 7166074 | Reghabit et al. | Jan 2007 | B2 |
| 7169289 | Schulein et al. | Jan 2007 | B2 |
| 7172075 | ji | Feb 2007 | B1 |
| 7192450 | Brauker et al. | Mar 2007 | B2 |
| 7225535 | Feldman et al. | Jun 2007 | B2 |
| 7226978 | Tapsak et al. | Jun 2007 | B2 |
| 7229471 | Gale et al. | Jun 2007 | B2 |
| 7241586 | Gulati | Jul 2007 | B2 |
| 7248906 | Dirac et al. | Jul 2007 | B2 |
| 7279174 | Pacetti et al. | Oct 2007 | B2 |
| 7335286 | Abel et al. | Feb 2008 | B2 |
| 7336984 | Gough et al. | Feb 2008 | B2 |
| 7344499 | Prausnitz et al. | Mar 2008 | B1 |
| 7357793 | Pacetti | Apr 2008 | B2 |
| 7364592 | Carr-Brendel et al. | Apr 2008 | B2 |
| 7366556 | Brister et al. | Apr 2008 | B2 |
| 7379765 | Petisce et al. | May 2008 | B2 |
| 7417164 | Suri | Aug 2008 | B2 |
| 7423074 | Lai et al. | Sep 2008 | B2 |
| 7426408 | DeNuzzio et al. | Sep 2008 | B2 |
| 7470488 | Lee et al. | Dec 2008 | B2 |
| 7471972 | Rhodes et al. | Dec 2008 | B2 |
| 7637868 | Saint et al. | Dec 2009 | B2 |
| 7651596 | Petisce et al. | Jan 2010 | B2 |
| 7657297 | Simpson et al. | Feb 2010 | B2 |
| 20020018843 | Van Antwerp et al. | Feb 2002 | A1 |
| 20020042090 | Heller et al. | Apr 2002 | A1 |
| 20020042561 | Schulman et al. | Apr 2002 | A1 |
| 20020043471 | Ikeda et al. | Apr 2002 | A1 |
| 20020055673 | Van Antwerp et al. | May 2002 | A1 |
| 20020123087 | Vachon et al. | Sep 2002 | A1 |
| 20020128419 | Terry et al. | Sep 2002 | A1 |
| 20020128546 | Silver | Sep 2002 | A1 |
| 20020151816 | Rich et al. | Oct 2002 | A1 |
| 20020169369 | Ward et al. | Nov 2002 | A1 |
| 20020185384 | Leong et al. | Dec 2002 | A1 |
| 20020188185 | Sohrab | Dec 2002 | A1 |
| 20030006669 | Pei et al. | Jan 2003 | A1 |
| 20030009093 | Silver | Jan 2003 | A1 |
| 20030023317 | Brauker et al. | Jan 2003 | A1 |
| 20030032874 | Rhodes et al. | Feb 2003 | A1 |
| 20030036773 | Whitehurst et al. | Feb 2003 | A1 |
| 20030059631 | Al-Lamee | Mar 2003 | A1 |
| 20030065254 | Schulman et al. | Apr 2003 | A1 |
| 20030069383 | Van Antwerp et al. | Apr 2003 | A1 |
| 20030070548 | Clausen | Apr 2003 | A1 |
| 20030088166 | Say et al. | May 2003 | A1 |
| 20030096424 | Mao et al. | May 2003 | A1 |
| 20030104273 | Lee et al. | Jun 2003 | A1 |
| 20030125498 | McCabe et al. | Jul 2003 | A1 |
| 20030125613 | Enegren et al. | Jul 2003 | A1 |
| 20030130616 | Steil et al. | Jul 2003 | A1 |
| 20030132227 | Geisler | Jul 2003 | A1 |
| 20030134100 | Mao et al. | Jul 2003 | A1 |
| 20030134347 | Heller et al. | Jul 2003 | A1 |
| 20030138674 | Zeikus et al. | Jul 2003 | A1 |
| 20030157409 | Huang et al. | Aug 2003 | A1 |
| 20030181794 | Rini et al. | Sep 2003 | A1 |
| 20030187338 | Say et al. | Oct 2003 | A1 |
| 20030199745 | Burson et al. | Oct 2003 | A1 |
| 20030199878 | Pohjonen | Oct 2003 | A1 |
| 20030203991 | Schottman et al. | Oct 2003 | A1 |
| 20030211050 | Majeti et al. | Nov 2003 | A1 |
| 20030211625 | Cohan | Nov 2003 | A1 |
| 20030217966 | Tapsak et al. | Nov 2003 | A1 |
| 20030225324 | Anderson et al. | Dec 2003 | A1 |
| 20030228681 | Ritts et al. | Dec 2003 | A1 |
| 20030235817 | Bartkowiak et al. | Dec 2003 | A1 |
| 20040006263 | Anderson et al. | Jan 2004 | A1 |
| 20040008761 | Kelliher et al. | Jan 2004 | A1 |
| 20040011671 | Shults et al. | Jan 2004 | A1 |
| 20040015063 | DeNuzzio et al. | Jan 2004 | A1 |
| 20040045879 | Shults et al. | Mar 2004 | A1 |
| 20040063167 | Kaastrup et al. | Apr 2004 | A1 |
| 20040074785 | Holker | Apr 2004 | A1 |
| 20040084306 | Shin et al. | May 2004 | A1 |
| 20040106741 | Kriesel et al. | Jun 2004 | A1 |
| 20040106857 | Gough | Jun 2004 | A1 |
| 20040111017 | Say et al. | Jun 2004 | A1 |
| 20040111144 | Lawin et al. | Jun 2004 | A1 |
| 20040120848 | Teodorczyk | Jun 2004 | A1 |
| 20040138543 | Russell et al. | Jul 2004 | A1 |
| 20040143173 | Reghabi et al. | Jul 2004 | A1 |
| 20040158138 | Kilcoyne et al. | Aug 2004 | A1 |
| 20040167801 | Say et al. | Aug 2004 | A1 |
| 20040176672 | Silver et al. | Sep 2004 | A1 |
| 20040180391 | Gratzl et al. | Sep 2004 | A1 |
| 20040186362 | Brauker et al. | Sep 2004 | A1 |
| 20040213985 | Lee et al. | Oct 2004 | A1 |
| 20040224001 | Pacetti et al. | Nov 2004 | A1 |
| 20040228902 | Benz | Nov 2004 | A1 |
| 20040234575 | Horres et al. | Nov 2004 | A1 |
| 20050013842 | Qiu et al. | Jan 2005 | A1 |
| 20050031689 | Shults et al. | Feb 2005 | A1 |
| 20050033132 | Shults et al. | Feb 2005 | A1 |
| 20050044088 | Lindsay et al. | Feb 2005 | A1 |
| 20050051427 | Brauker et al. | Mar 2005 | A1 |
| 20050051440 | Simpson et al. | Mar 2005 | A1 |
| 20050054909 | Petisce et al. | Mar 2005 | A1 |
| 20050056552 | Simpson et al. | Mar 2005 | A1 |
| 20050070770 | Dirac et al. | Mar 2005 | A1 |
| 20050077584 | Uhland et al. | Apr 2005 | A1 |
| 20050079200 | Rathenow et al. | Apr 2005 | A1 |
| 20050090607 | Tapsak et al. | Apr 2005 | A1 |
| 20050096519 | DeNuzzio et al. | May 2005 | A1 |
| 20050103625 | Rhodes et al. | May 2005 | A1 |
| 20050107677 | Ward et al. | May 2005 | A1 |
| 20050112169 | Brauker et al. | May 2005 | A1 |
| 20050112172 | Pacetti | May 2005 | A1 |
| 20050112358 | Potyrailo et al. | May 2005 | A1 |
| 20050115832 | Simpson et al. | Jun 2005 | A1 |
| 20050118344 | Pacetti | Jun 2005 | A1 |
| 20050119720 | Gale et al. | Jun 2005 | A1 |
| 20050121322 | Say | Jun 2005 | A1 |
| 20050124873 | Shults et al. | Jun 2005 | A1 |
| 20050139489 | Davies et al. | Jun 2005 | A1 |
| 20050143635 | Kamath et al. | Jun 2005 | A1 |
| 20050154272 | Dirac et al. | Jul 2005 | A1 |
| 20050173245 | Feldman et al. | Aug 2005 | A1 |
| 20050176136 | Burd et al. | Aug 2005 | A1 |
| 20050176678 | Horres et al. | Aug 2005 | A1 |
| 20050177036 | Shults et al. | Aug 2005 | A1 |
| 20050181012 | Saint et al. | Aug 2005 | A1 |
| 20050182451 | Griffin et al. | Aug 2005 | A1 |
| 20050184641 | Armitage et al. | Aug 2005 | A1 |
| 20050196747 | Stiene | Sep 2005 | A1 |
| 20050197554 | Polcha | Sep 2005 | A1 |
| 20050209665 | Hunter et al. | Sep 2005 | A1 |
| 20050211571 | Schulein et al. | Sep 2005 | A1 |
| 20050233407 | Pamidi et al. | Oct 2005 | A1 |
| 20050239154 | Feldman et al. | Oct 2005 | A1 |
| 20050242479 | Petisce et al. | Nov 2005 | A1 |
| 20050245795 | Goode et al. | Nov 2005 | A1 |
| 20050245799 | Brauker et al. | Nov 2005 | A1 |
| 20050251083 | Carr-Brendel et al. | Nov 2005 | A1 |
| 20050271546 | Gerber et al. | Dec 2005 | A1 |
| 20050272989 | Shah et al. | Dec 2005 | A1 |
| 20050274665 | Heilmann et al. | Dec 2005 | A1 |
| 20050282997 | Ward | Dec 2005 | A1 |
| 20060003398 | Heller et al. | Jan 2006 | A1 |
| 20060007391 | McCabe et al. | Jan 2006 | A1 |
| 20060008370 | Massaro et al. | Jan 2006 | A1 |
| 20060015020 | Neale et al. | Jan 2006 | A1 |
| 20060016700 | Brister et al. | Jan 2006 | A1 |
| 20060019327 | Brister et al. | Jan 2006 | A1 |
| 20060020186 | Brister et al. | Jan 2006 | A1 |
| 20060036140 | Brister et al. | Feb 2006 | A1 |
| 20060047095 | Pacetti | Mar 2006 | A1 |
| 20060058868 | Gale et al. | Mar 2006 | A1 |
| 20060065527 | Samproni | Mar 2006 | A1 |
| 20060067908 | Ding | Mar 2006 | A1 |
| 20060068208 | Tapsak et al. | Mar 2006 | A1 |
| 20060078908 | Pitner et al. | Apr 2006 | A1 |
| 20060079740 | Silver et al. | Apr 2006 | A1 |
| 20060086624 | Tapsak et al. | Apr 2006 | A1 |
| 20060134165 | Pacetti | Jun 2006 | A1 |
| 20060142524 | Lai et al. | Jun 2006 | A1 |
| 20060142525 | Lai et al. | Jun 2006 | A1 |
| 20060142526 | Lai et al. | Jun 2006 | A1 |
| 20060142651 | Brister et al. | Jun 2006 | A1 |
| 20060148985 | Karthauser | Jul 2006 | A1 |
| 20060155180 | Brister et al. | Jul 2006 | A1 |
| 20060159718 | Rathenow et al. | Jul 2006 | A1 |
| 20060171980 | Helmus et al. | Aug 2006 | A1 |
| 20060177379 | Asgari | Aug 2006 | A1 |
| 20060183178 | Gulati | Aug 2006 | A1 |
| 20060183871 | Ward et al. | Aug 2006 | A1 |
| 20060189856 | Petisce et al. | Aug 2006 | A1 |
| 20060195029 | Shults et al. | Aug 2006 | A1 |
| 20060198864 | Shults et al. | Sep 2006 | A1 |
| 20060200019 | Petisce et al. | Sep 2006 | A1 |
| 20060200022 | Brauker et al. | Sep 2006 | A1 |
| 20060200970 | Brister et al. | Sep 2006 | A1 |
| 20060204536 | Shults et al. | Sep 2006 | A1 |
| 20060211921 | Brauker et al. | Sep 2006 | A1 |
| 20060222566 | Brauker et al. | Oct 2006 | A1 |
| 20060224108 | Brauker et al. | Oct 2006 | A1 |
| 20060229512 | Petisce et al. | Oct 2006 | A1 |
| 20060249381 | Petisce et al. | Nov 2006 | A1 |
| 20060249446 | Yeager | Nov 2006 | A1 |
| 20060249447 | Yeager | Nov 2006 | A1 |
| 20060252027 | Petisce et al. | Nov 2006 | A1 |
| 20060253012 | Petisce et al. | Nov 2006 | A1 |
| 20060257995 | Simpson et al. | Nov 2006 | A1 |
| 20060257996 | Simpson et al. | Nov 2006 | A1 |
| 20060258761 | Boock et al. | Nov 2006 | A1 |
| 20060258929 | Goode et al. | Nov 2006 | A1 |
| 20060263673 | Kim et al. | Nov 2006 | A1 |
| 20060263763 | Simpson et al. | Nov 2006 | A1 |
| 20060263839 | Ward et al. | Nov 2006 | A1 |
| 20060269586 | Pacetti | Nov 2006 | A1 |
| 20060270922 | Brauker et al. | Nov 2006 | A1 |
| 20060270923 | Brauker et al. | Nov 2006 | A1 |
| 20060275857 | Kjaer et al. | Dec 2006 | A1 |
| 20060275859 | Kjaer | Dec 2006 | A1 |
| 20060281985 | Ward et al. | Dec 2006 | A1 |
| 20060289307 | Yu et al. | Dec 2006 | A1 |
| 20060293487 | Gaymans et al. | Dec 2006 | A1 |
| 20070003588 | Chinn et al. | Jan 2007 | A1 |
| 20070007133 | Mang et al. | Jan 2007 | A1 |
| 20070027370 | Brauker et al. | Feb 2007 | A1 |
| 20070027385 | Brister et al. | Feb 2007 | A1 |
| 20070032717 | Brister et al. | Feb 2007 | A1 |
| 20070032718 | Shults et al. | Feb 2007 | A1 |
| 20070038044 | Dobbles et al. | Feb 2007 | A1 |
| 20070045902 | Brauker et al. | Mar 2007 | A1 |
| 20070059196 | Brister et al. | Mar 2007 | A1 |
| 20070123963 | Krulevitch | May 2007 | A1 |
| 20070129524 | Sunkara | Jun 2007 | A1 |
| 20070135698 | Shah et al. | Jun 2007 | A1 |
| 20070142584 | Schorzman et al. | Jun 2007 | A1 |
| 20070155851 | Alli et al. | Jul 2007 | A1 |
| 20070161769 | Schorzman et al. | Jul 2007 | A1 |
| 20070163880 | Woo et al. | Jul 2007 | A1 |
| 20070166343 | Goerne et al. | Jul 2007 | A1 |
| 20070166364 | Beier et al. | Jul 2007 | A1 |
| 20070173709 | Petisce et al. | Jul 2007 | A1 |
| 20070173710 | Petisce et al. | Jul 2007 | A1 |
| 20070173711 | Shah et al. | Jul 2007 | A1 |
| 20070197890 | Boock et al. | Aug 2007 | A1 |
| 20070200267 | Tsai | Aug 2007 | A1 |
| 20070202562 | Curry | Aug 2007 | A1 |
| 20070203568 | Gale et al. | Aug 2007 | A1 |
| 20070203966 | Brauker et al. | Aug 2007 | A1 |
| 20070213611 | Simpson et al. | Sep 2007 | A1 |
| 20070215491 | Heller et al. | Sep 2007 | A1 |
| 20070218097 | Heller et al. | Sep 2007 | A1 |
| 20070227907 | Shah et al. | Oct 2007 | A1 |
| 20070229757 | McCabe et al. | Oct 2007 | A1 |
| 20070233013 | Schoenberg | Oct 2007 | A1 |
| 20070235331 | Simpson et al. | Oct 2007 | A1 |
| 20070242215 | Schorzman et al. | Oct 2007 | A1 |
| 20070244379 | Boock et al. | Oct 2007 | A1 |
| 20070259217 | Logan | Nov 2007 | A1 |
| 20070275193 | DeSimone et al. | Nov 2007 | A1 |
| 20070299385 | Santini et al. | Dec 2007 | A1 |
| 20070299409 | Whibourne et al. | Dec 2007 | A1 |
| 20080001318 | Schorzman et al. | Jan 2008 | A1 |
| 20080021008 | Pacetti et al. | Jan 2008 | A1 |
| 20080021666 | Goode et al. | Jan 2008 | A1 |
| 20080027301 | Ward et al. | Jan 2008 | A1 |
| 20080031918 | Lawin et al. | Feb 2008 | A1 |
| 20080033269 | Zhang | Feb 2008 | A1 |
| 20080034972 | Gough et al. | Feb 2008 | A1 |
| 20080038307 | Hoffmann | Feb 2008 | A1 |
| 20080045824 | Tapsak et al. | Feb 2008 | A1 |
| 20080071027 | Pacetti | Mar 2008 | A1 |
| 20080076897 | Kunzler et al. | Mar 2008 | A1 |
| 20080081184 | Kubo et al. | Apr 2008 | A1 |
| 20080113207 | Pacetti et al. | May 2008 | A1 |
| 20080138497 | Pacetti et al. | Jun 2008 | A1 |
| 20080138498 | Pacetti et al. | Jun 2008 | A1 |
| 20080143014 | Tang | Jun 2008 | A1 |
| 20080187655 | Markle et al. | Aug 2008 | A1 |
| 20080188722 | Markle et al. | Aug 2008 | A1 |
| 20080188725 | Markle et al. | Aug 2008 | A1 |
| 20080210557 | Heller et al. | Sep 2008 | A1 |
| 20080213460 | Benter et al. | Sep 2008 | A1 |
| 20080228051 | Shults et al. | Sep 2008 | A1 |
| 20080228054 | Shults et al. | Sep 2008 | A1 |
| 20080242961 | Brister et al. | Oct 2008 | A1 |
| 20080262334 | Dunn et al. | Oct 2008 | A1 |
| 20080305009 | Gamsey et al. | Dec 2008 | A1 |
| 20080305506 | Suri | Dec 2008 | A1 |
| 20080306368 | Goode et al. | Dec 2008 | A1 |
| 20080312397 | Lai et al. | Dec 2008 | A1 |
| 20090004243 | Pacetti et al. | Jan 2009 | A1 |
| 20090012205 | Nakada et al. | Jan 2009 | A1 |
| 20090012379 | Goode et al. | Jan 2009 | A1 |
| 20090018418 | Markle et al. | Jan 2009 | A1 |
| 20090018426 | Markle et al. | Jan 2009 | A1 |
| 20090030294 | Petisce et al. | Jan 2009 | A1 |
| 20090036763 | Brauker et al. | Feb 2009 | A1 |
| 20090045055 | Rhodes et al. | Feb 2009 | A1 |
| 20090061528 | Suri | Mar 2009 | A1 |
| 20090062633 | Brauker et al. | Mar 2009 | A1 |
| 20090081803 | Gamsey et al. | Mar 2009 | A1 |
| 20090177143 | Markle et al. | Jul 2009 | A1 |
| 20090247855 | Boock et al. | Oct 2009 | A1 |
| 20090247856 | Boock et al. | Oct 2009 | A1 |
| 20090264719 | Markle et al. | Oct 2009 | A1 |
| 20090287073 | Boock et al. | Nov 2009 | A1 |
| 20100041971 | Goode, Jr. et al. | Feb 2010 | A1 |
| 20100049024 | Saint et al. | Feb 2010 | A1 |
| 20100076283 | Simpson et al. | Mar 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 098 592 | Jan 1984 | EP |
| 0 127 958 | Dec 1984 | EP |
| 0 291 130 | Nov 1988 | EP |
| 0 313 951 | May 1989 | EP |
| 0 320 109 | Jun 1989 | EP |
| 0 353 328 | Feb 1990 | EP |
| 0 362 145 | Apr 1990 | EP |
| 0 390 390 | Oct 1990 | EP |
| 0 396 788 | Nov 1990 | EP |
| 0 534 074 | Mar 1993 | EP |
| 0 535 898 | Apr 1993 | EP |
| 0 539 625 | May 1993 | EP |
| 0 563 795 | Oct 1993 | EP |
| 0 817 809 | Jan 1998 | EP |
| 0 862 648 | Sep 1998 | EP |
| 0 967 788 | Dec 1999 | EP |
| 2656423 | Jun 1991 | FR |
| 2760962 | Sep 1998 | FR |
| 2149918 | Jun 1985 | GB |
| 2209836 | May 1989 | GB |
| 57156004 | Sep 1982 | JP |
| 57156005 | Sep 1982 | JP |
| 58163402 | Sep 1983 | JP |
| 58163403 | Sep 1983 | JP |
| 59029693 | Feb 1984 | JP |
| 59049803 | Mar 1984 | JP |
| 59049805 | Mar 1984 | JP |
| 59059221 | Apr 1984 | JP |
| 59087004 | May 1984 | JP |
| 59-211459 | Nov 1984 | JP |
| 59209608 | Nov 1984 | JP |
| 59209609 | Nov 1984 | JP |
| 59209610 | Nov 1984 | JP |
| 60245623 | Dec 1985 | JP |
| 61238319 | Oct 1986 | JP |
| 62074406 | Apr 1987 | JP |
| 62083649 | Apr 1987 | JP |
| 62102815 | May 1987 | JP |
| 62227423 | Oct 1987 | JP |
| 63130661 | Jun 1988 | JP |
| 01018404 | Jan 1989 | JP |
| 01018405 | Jan 1989 | JP |
| 02002913 | Jan 1990 | JP |
| 3-293556 | Dec 1991 | JP |
| 05279447 | Oct 1993 | JP |
| 07-083871 | Mar 1995 | JP |
| 8196626 | Aug 1996 | JP |
| 62083849 | Apr 1997 | JP |
| 2002-189015 | Jul 2002 | JP |
| WO 8902720 | Apr 1989 | WO |
| WO 9000738 | Jan 1990 | WO |
| WO 9007575 | Jul 1990 | WO |
| WO 9109302 | Jun 1991 | WO |
| WO 9207525 | May 1992 | WO |
| WO 9213271 | Aug 1992 | WO |
| WO 9314185 | Jul 1993 | WO |
| WO 9314693 | Aug 1993 | WO |
| WO 9319701 | Oct 1993 | WO |
| WO 9323744 | Nov 1993 | WO |
| WO 9408236 | Apr 1994 | WO |
| WO 9422367 | Oct 1994 | WO |
| WO 9601611 | Jan 1996 | WO |
| WO 9614026 | May 1996 | WO |
| WO 9625089 | Aug 1996 | WO |
| WO 9630431 | Oct 1996 | WO |
| WO 9632076 | Oct 1996 | WO |
| WO 9636296 | Nov 1996 | WO |
| WO 9701986 | Jan 1997 | WO |
| WO 9711067 | Mar 1997 | WO |
| WO 9743633 | Nov 1997 | WO |
| WO 9824358 | Jun 1998 | WO |
| WO 9838906 | Sep 1998 | WO |
| WO 9956613 | Apr 1999 | WO |
| WO 0013003 | Mar 2000 | WO |
| WO 0019887 | Apr 2000 | WO |
| WO 0032098 | Jun 2000 | WO |
| WO 0033065 | Jun 2000 | WO |
| WO 0059373 | Oct 2000 | WO |
| WO 0074753 | Dec 2000 | WO |
| WO 0112158 | Feb 2001 | WO |
| WO 0143660 | Jun 2001 | WO |
| WO 02053764 | Jul 2002 | WO |
| WO 2005012873 | Feb 2005 | WO |
| WO 2005045394 | May 2005 | WO |
| WO 2005057168 | Jun 2005 | WO |
| WO 2005026689 | Oct 2005 | WO |
| WO 2006018425 | Feb 2006 | WO |
| WO 2007114943 | Oct 2007 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20100099970 A1 | Apr 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 08811473 | Mar 1997 | US |
| Child | 09447227 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09447227 | Nov 1999 | US |
| Child | 12645097 | US |
